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ABSTRACT 
 
Morgan Chateau: HIV Transmission Prevention 
(Under the direction of Dr. J. Victor Garcia) 
 
 The human immunodeficiency virus (HIV) infects and replicates within individuals for 
the duration of their life. Initial infection results in little to no symptoms for years or even 
decades. These individuals are infectious and capable of further spreading HIV while completely 
unaware of their own status. This ability to transmit without detection is what lead to the 
unknown and thereby unopposed global spread of HIV type one (HIV-1). Once a test was 
developed to detect HIV, the virus was found in nearly all major countries around the world. 
Development of a cure has proven to be exceedingly difficult. So far, the only successful tactic to 
reduce the number of infected HIV individuals has been to prevent HIV transmission. 
Traditionally, the most effective way to prevent viral transmission is with a vaccine, but an 
effective HIV vaccine for wide spread use has not been developed. Therefore, alternative HIV 
transmission prevention strategies have been used. These strategies largely depend on behavioral 
modifications and include: 1) utilization of universal precautions in medical settings, 2) 
increased emphasis on HIV testing and self awareness of infection status, 3) encouraged use of 
protective measures such as condoms and male circumcision, 4) prophylactic use of 
antiretroviral drugs to limit mother to child transmission MTCT, and 5) the newly available oral 
pre-exposure prophylactic use of Truvada in HIV negative individuals. Together, these strategies 
have contributed to nearly eliminating HIV transmission in medical settings and greatly reduced 
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MTCT. Unfortunately, HIV continues to spread globally largely due to sexual transmission. 
While condom usage is highly efficient to prevent transmission, their use is limited by 
acceptability and consent. In this dissertation, I evaluated the potential of topically applied 
interventions to be a novel, effective form of protection against HIV transmission as well as 
established a novel line of investigation evaluating microbial contributions to HIV transmission.  
 Using humanized mice as a model of HIV transmission, I evaluated two antiretroviral 
drug based topical pre-exposure prophylaxis (PrEP) for efficacy; tenofovir and maraviroc. In 
both instances, these drugs were found to be protective when used prior to HIV exposure. 
Concerns regarding the dual use of tenofovir for treatment as well as PrEP prompted me to 
evaluate transmission of a tenofovir resistant strain of HIV. This study demonstrated a 
surprisingly large defect in transmission for tenofovir resistant HIV, which suggests that use of 
Tenofovir for PrEP may not result in a significant increase of circulating tenofovir resistant 
strains of HIV.  
 I also utilized the humanized mouse model to start a completely novel line of 
investigation evaluating the effect of microbial populations on HIV transmission. While these 
studies are ongoing, preliminary results have shown a clear effect of microbiome composition on 
rectal HIV transmission. These results are significant in two ways. First, this is the first evidence 
that humanized mice are viable tools for microbiome based studies. Second, commensal 
microbiota does affect HIV transmission efficiency. 
 Taken together, the following dissertation supports further efforts to curb the HIV 
epidemic by development of topical interventions (microbicides) and lends credence toward 
interventions based on commensal microbiome manipulations. 
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CHAPTER I. INTRODUCTION 
 
HIV PREVENTION: STRATEGIES CURRENTLY IN USE  
 
  The greatest progress to stemming the HIV/AIDS epidemic has been to prevent HIV 
transmission. There are three main routes HIV transmission can occur: 1) wound/intravenous, 2) 
mother-to-child, and 3) sexual contact. Of these routes, sexual transmission of HIV is the 
greatest driving force of the epidemic. 
  
Preventing Sexual HIV Transmission 
 There were 2.3 million new HIV infections in 2012 [1]. The majority of these 
transmissions were the result of sexual exposure to HIV. Preventative methods such as the use of 
condoms, male circumcision, and attempts to modify behavior through awareness and education 
have been used to help limit HIV transmission through sexual contact [1-3] .  
 With the exception of abstinence, the most efficient method to prevent sexual HIV 
transmission is by proper condom use [4]. Male condoms that are used correctly are 95% 
effective at preventing HIV transmission [4]. Since male condoms are often not used correctly, 
the average efficacy drops to 70% prevention of HIV transmission [5]. In addition to preventing 
HIV transmission, condoms can reduce the transmission of other sexually transmitted diseases 
such as gonorrhea [6, 7]. Factors that limit effective condom use include 1) improper technique, 
2) availability of quality condoms that are affordable, and 3) having a partner willing to use a 
condom. Improper condom use includes failure to keep condom on for the entire duration of the 
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sexual encounter, incorrect sizing or placement resulting in slippage, and failure to use a condom 
for every sexual encounter [6]. Availability of quality, non-expired condoms at an affordable 
price is a major concern in underdeveloped nations [8]. Ultimately,  condom use in both under 
developed and fully developed nations requires  male partner acceptance . A study done at an 
urban clinic in the U.S. reported that 33% of male patients receiving treatment for a STD did not 
feel motivated to use a condom consistently [7]. Studies investigating condom usage among sex 
workers have shown an increase in consistent condom usage with clients but a disappointing lack 
of condom usage with non-paying, regular partners such as boyfriends and husbands [9]. 
 An additional biomedical intervention found to help reduce the HIV transmission risk is 
male circumcision. The ANRS 1265 trial done in South Africa reported a 60% protection in men 
who underwent circumcision [10]. A second trial of 2784 men in Kenya found the same level of 
protection [11].  A third clinical trial in Uganda also found male circumcision to be 55% 
protective for men with circumcisions [12]. The results of these three trials in addition to other 
studies prompted the WHO and UNAIDS  to jointly recommend male circumcision as an 
effective prevention for HIV transmission to men although consistent, proper condom use 
strongly encouraged [13]. Unfortunately, male to female transmission is not reduced by male 
circumcision. 
 While each of these methods presented in this chapter have shown progress, they are 
male/penetrative partner controlled and largely limited by acceptability. Therefore, great efforts 
are in progress to develop alternative, potentially more acceptable methods for HIV prevention 
that can be used by the female or receptive partner. 
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HIV TRANSMISSION PREVENTION: ANTIRETROVIRAL BASED STRATAEGIES 
UNDER INVESTIGATION 
 
 
  For several years, abstinence, condom use, and male circumcision were the main 
methods available to prevent sexual transmission of HIV.  Over the past decade, several 
antiretroviral dug based strategies have been under investigation for effective HIV prevention. In 
general, these strategies can be divided by route of administration; oral, topical, or injectable.  
 
Treatment as Prevention 
 Current NIH guidelines support the initiation of ART at any stage of HIV infection but 
places especially strong recommendation to start ART when CD4 cell counts drop below 500 
cells/mm
3
. An HIV infected individual could delay starting ART for years so long as their CD4+ 
T cell count remains high enough to result in an effective immune response, thereby delaying the 
inevitable pill burden and possible complications of being on ART. This makes sense from the 
individual treatment perspective, but in terms of public health, initiating ART early could help 
reduce the number of HIV transmissions in the population.  
 In 2011, the results of the HIV Prevention Trials Network (HPTN) 052 clinical trial 
showed a 96% reduction in HIV transmission between sero-discordant couples when the HIV 
infected partner started ART early [14]. This study provided the key scientific evidence needed 
to encourage “treatment as prevention” strategies [15]. A key component for treatment as 
prevention is the HIV positive person must be diagnosed. Unfortunately, of the HIV-infected 
people in the USA, only 4 of 5 are aware they are infected [16]. Therefore, for treatment as 
prevention to be effective against the HIV/AIDS epidemic a greater emphasis on HIV testing   
with linkage to care will be necessary. 
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Oral PrEP 
 In 2012, the first drug-based HIV prevention option, Truvada, was approved for 
prophylactic use in the U.S. [17]. Truvada is a single pill containing two drugs; tenofovir 
disoproxil fumarate (TDF) and emtricitabine (FTC). Truvada has been and still is heavily 
prescribed to HIV-infected patients as part of their first-line therapy. Its approval for 
prophylactic use was based on results of the iPREX, Partners PrEP, and TDF2 clinical trials 
where oral use of Truvada in HIV-negative individuals resulted in reduced transmission of HIV 
[18-20]. Rates of protection increased when adherence was taken into account [18, 21]. In the 
iPREX clinical trial, Truvada prevented 47% of infections when given to high risk HIV negative 
men who have sex with men [19]. This protection rose to 90% when investigators excluded 
participants who did not have detectable drug in their blood samples collected during study visits 
[19]. Therefore, participants who actually took the drug as prescribed had a very high level of 
protection from HIV infection. Partners PrEP reported a 75% protection when Truvada was 
prescribed to the HIV-negative individual in a serodicordant couple [22]. Adherence was very 
high in this study, 97%, which investigators attribute to co-counseling of the couples, awareness 
of partner’s HIV infection, and the tendency for individuals in a relationship to encourage dosing 
[22, 23]. The TDF2 trial enrolled sexually active men and women in Botswana and reported a 
62% protection for those who were instructed to take daily Truvada [24]. A fourth major clinical 
trial evaluating Truvada for PrEP, FEM-PREP, did not show protection but was terminated early 
due to poor adherence [25].  
 The failure of FEM-PREP highlights a very important issue. The efficacy of oral PrEP 
strategies is greatly undermined by poor adherence [23]. Adherence, as determined by detectable 
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drug levels in blood samples, was highest in the Partners PrEP study (≈90%) and lowest in FEM-
PREP (≈30%) [22, 24]. One theory to explain this vast difference in adherence is that 
participants had a very different perception of the possibility of HIV infection. Participants in the 
Partners PrEP study were chosen because they were sexually active with a partner who was 
known to be HIV positive. Participants believed themselves to be at high risk of HIV acquisition. 
This is a stark contrast to the FEM PREP study where 70% of the participants felt they were “at 
little to no risk” of acquiring HIV [26].   
 The efficacy found in iPREX, Partners PrEP, and TDF2 was sufficient for the FDA to 
approve Truvada for use as PrEP. Unfortunately, prescription of Truvada for use as PrEP has 
been disappointingly low. Reports have suggested several factors limiting the number of 
prescriptions for Truvada as PrEP. Despite the release of guidelines by the CDC, clinicians have 
demonstrated considerable variability in their opinions and decision to prescribe [27]. Despite 
the availability of official sources of information, at risk individuals may be unaware of the 
availability of Truvada for PrEP, miss-informed regarding its prescription, or simply unaware 
that they are “at-risk”. In addition, stigma also plays a strong role. Critics of Truvada as PrEP 
have argued that prescribing HIV PrEP will result in greater promiscuity. Supporters of Truvada 
as PrEP argue that prescribing HIV PrEP is an act of being responsible for one’s own health. It 
may take several years for the medical and general population to support Truvada as PrEP. 
  
TOPICAL PREP/ MICROBICIDES  
 Topical PrEP or microbicides are a gel, liquid, foam, or dissolving sheet designed 
to be used vaginally and/or rectally to prevent HIV transmission. There are multiple reasons why 
microbicides are attractive as tools for HIV prevention: (i) microbicides are user controlled [28]; 
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(iv) microbicides are predicted to be cost-effective [29, 30] local administration of an 
antiretroviral gel at the site of exposure will result in higher drug levels at the intended 
anatomical location than can be achieved using oral PrEP [28, 31-33] while reducing the 
likelihood of experiencing systemic dosing-associated toxicities [33, 34]; (ii) the reduced toxicity 
associated with topical microbicides is expected to increase adherence [35]; (iii); (v) topical 
microbicides can be developed with combinations of viral inhibitors [36]; (vi) an ideal 
microbicide would be safe and effective in both rectal and vaginal compartments [37-39]; and 
(vii) antiviral microbicides may also protect against viruses other than HIV (e.g. herpes simplex) 
[40, 41]. 
  
Topical Microbicides that Failed: what can we learn? 
 Clinical trials evaluating the use of topical microbicides to prevent HIV transmission 
have shown mixed results. Initial clinical trials were focused on utilizing spermicidal agents to 
prevent vaginal transmission of HIV while also preventing pregnancy. Nonoxynal-9 (N-9) is a 
detergent-type vaginal spermicide available without a prescription. Clinical trials of N-9 found 
an average 75% effective at preventing pregnancy [42-44]. N-9’s mechanism of action for 
preventing impregnation is to destroy a lipid membrane, the acrosome, of sperm cells thereby 
rendering them immobile. In theory, investigators believed this same ability to break down lipid 
membranes would affect the lipid membrane surrounding the HIV virion thereby rendering the 
particle unable to bind/merge with a target cell [45]. In 1985 and 1988, N-9 was reported to be 
effective at reducing HIV infection in in vitro [46, 47]. Based on these results, several 
investigators recommended the use of N-9 to prevent HIV transmission to women [48-50]. In a 
clinical trial of commercial sex workers in Nairobi, the women who used N-9 containing sponges 
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had a 10% higher rate of HIV acquisition compared to the placebo group [51]. This increase in 
HIV acquisition may have been due to the epithelial damage experienced with N-9 use resulting 
in increased frequency of genital ulcers and vulvitis reported with N-9 use [51, 52]. This 
exfoliating effect of N-9 was also observed when N-9 containing products are applied rectally 
and also results in increased viral transmission [53-56]. Therefore, N-9 has been discarded as 
completely unsuitable for topical HIV prevention [55]. This study has made it clear that future 
microbicides must not induce breaks in epithelial integrity or induce an inflammatory response. 
 Alternative "first-generation" microbicides that have undergone Phase I/II safety and 
tolerability studies in HIV-uninfected and/or HIV-infected volunteers include polymeric viral 
fusion inhibitors (dextran sulfate/Emmelle, carrageenans [PC-213, PC-503, PC-515/Carraguard], 
cellulose sulfate/Ushercell, polystyrene sulfonate, naphthalene sulfonate [PIC 024-4/PRO 
2000/5], acidifying gel [Carbomer 974P/BufferGel], Lactobacillus (L. crispatus) 
suppository/CTV-05, detergent-type dual-function barriers [ACIDFORM, GEDA Plus, 
SURETE, Glyminox/C31G/Savvy, Invisible Condom], and  herbal extracts [Praneem] [57]. 
While all of these microbicides were proven effective in vitro or in cell culture, none of them 
passed human efficacy trials.  
 Much like N-9, cellulose sulfate based microbicides, like Ushercell, were developed to 
act as both a birth control and protection against STD acquisition [58]. Unlike N-9, Ushercell did 
not induce epithelial sloughing or ulcers. Cellulose sulfate is a polyanionic compound from the 
carrageenan family that binds charged surfaces in a non-specific manor. These types of 
molecules are used by many microbes for initial attachment to cell membranes. In theory, a gel 
with cellulose sulfate will result in sperm and infectious virions binding to the compounds in the 
gel rather than to target cells [59, 60]. In the rabbit model, Ushercell was found to be an effective 
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contraceptive capable of preventing 95-100% of pregnancies [58]. This same paper reported 
Ushercell to be non-toxic to host cells or to Lactobacilli growth [58]. In vitro, Ushercell had 
several anti-microbial effects on herpes viruses, IC50 = 59ng/mL for HSV-1 and IC50= 24 ng/mL 
for HSV-2, on HIV, IC50 between 3 and 78 ug/mL for various HIV strains, on Neisseria 
gonorrhoeae, IC50= 2 ug/mL, and on Chlamydia trachomatic, IC50 = 78 ug/mL [58]. Multiple 
phase I and II safety trials were done for vaginal application of Ushercell and reported no safety 
concerns [61, 62]. One study evaluated Ushercell use in HIV infected women. While the 
investigators concluded there to be no safety issue, it should be noted that 70% of study 
participants reported minor to mild adverse events in both the experimental and the control arms 
of the study [62]. Another study evaluated the safety of Ushercell when applied to the penis of 
HIV infected men [63]. In this study, the investigators reported the gel to be “well tolerated” 
despite 42% of Ushercell users reporting adverse events such as itching, burning, testicular pain, 
dysuria, and warm/cold feelings [63]. In 2007, two phase III trials evaluating cellulose sulfate 
based microbicides were terminated early due to an increased risk of HIV acquisition in 
participants using the cellulose sulphate gel, Ushercell. In one of these studies, the Ushercell gel 
was being tested on 1333 women in Benin, India, South Africa, and Uganda as collaboration 
with Conrad, the Eastern Virginia Medical School, and the US Agency for International 
Development with funding from the Bill and Melinda Gates Foundation [64]. The second study 
was being conducted by Family Health International in Nigeria on 1800 women [64]. At the 
time, the FHI study did not have an increase HIV risk with Ushercell, but the study was stopped 
given the preliminary results in the Conrad trial [64]. What data was collected from the Conrad 
trial indicated that Ushercell was not preventing HIV transmission and that overall rate of 
adherence to gel was low; 50% of sexual encounters without a condom [65]. 
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 Dextran/dextrin sulfate is another polyanionic compound that was found effective in cell 
culture HIV protection assays [66]. Unfortunately, it is not absorbed well when given in oral 
dose [67]. To investigate the anti-HIV potential of dextran sulfate, one study administered the 
drug via continual intravenous dosing to HIV positive patients [68].  Despite achieving plasma 
drug levels 200 fold greater than the in vitro IC50, the patients exhibited an increase in 
detectable viral p24 [68]. In addition, continual dosing resulted in high toxicity [68]. Topical gel 
formulation of dextrin sulfate (Emmelle) was found to be safe when applied to the vagina or the 
penis of healthy volunteers [69-71]. Before starting a Phase III efficacy trial under the UK’s 
Microbicides Development Programme (MDP), ML laboratories , the makers of Emmelle, 
announced that they would abandon development of Emmelle in favor of a newer, more potent 
microbicide, PRO 2000 [72]. 
 PR0 2000 was a naphthalene sulfonate polymer containing gel developed by Interneuron. 
This polyanionic compound had been shown to bind directly to the HIV gp120 protein  and 
interfere with viral attachment/fusion [73]. In tissue culture studies PRO 2000 was found to be 
highly potent and did not generate a cytotoxic effect [74]. As mentioned above, PRO 2000 was 
evaluated for efficacy in a MDP clinical study [75]. MDP-301 was a three arm study performed 
in South Africa, Tanzania, Uganda and Zambia. Women were randomly assigned to receive 
either a 0.5% PRO2000, 2.0% PRO2000, or a placebo gel and instructed to use the gel (available 
in single use applicators) within one hour before sexual intercourse [75]. Participants were 
followed for 52 weeks and evaluated for HIV status. While the gel was well tolerated, it was 
completely ineffective at preventing HIV transmission and the trial was terminated early [75, 
76]. Despite this, interesting data was collected regarding adherence. Adherence to orally 
administered drugs can be estimated by the presence of drug in the blood. Adherence to topically 
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administered interventions may not result in detectable levels of drug in the blood stream. In this 
clinical trial, in addition to self-reporting gel use, women were asked to bring one used applicator 
to each study visit. These applicators were then stained using a 1% trypan blue solution and 
evaluated for whether or not they were vaginally inserted [77]. This test had previously been 
found to be fairly accurate and offered a novel aspect to the MDP-301 study [77]. Participants in 
the MDP-301 study were only considered to have used the gel consistently if they filled three 
criterion i) self-reported consistent gel use, ii) presented a used vaginal applicator at each study 
visit, and iii) attendance of at least half of all study visits. Adherence, and how it is determined, 
will play a large role in clinical study design and interpretation of results. MDP-301 was one of 
the first topical microbicide trials to measure adherence using a criterion beyond self-reporting 
and applicator count. 
 Carraguard (PC-515) was developed by the Population Council in New York and, much 
like PRO2000, was designed to inhibit viral binding/fusion to target cells. In 2008, the results of 
a clinical trial involving over 6,000 participants found Carraguard to be safe but ineffective at 
preventing HIV transmission [78]. While this study did not find efficacy, it provided useful 
information regarding acceptance and adherence. In this study, self-reporting of gel use was very 
high (96.2% Carraguard arm, 95.9% placebo arm) but analysis of used applicators estimated a 
far lower adherence (41.1% Carraguard arm, 43.1% placebo arm) [78]. This is a lower adherence 
that what was reported for the previous MDP-301 study. It has been suggested that adherence 
was higher in MDP-301 due to the recruitment of sero-disordant couples where the study 
participant is fully aware of their partner’s HIV infection. 
 BufferGel is a product designed to maintain an acidic environment in the vagina. A pH 
value around 4 is considered healthy for the vaginal cavity and may kill or inactivate potential 
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pathogens. During sexual acts, the alkalinity of semen may temporarily raise the pH thereby 
removing some of the antimicrobial protection. BufferGel was tested for safety and efficacy in 
multiple animal models. When used in rabbits, BufferGel was an effective contraceptive and 
reduced transmission of rabbit papillomavirus [79]. When used in mice, BufferGel prevented 
vaginal transmission of Chlamydia trachomatis but did not prevent transmission of Neisseria 
gonorrhoeae [79]. When tested vaginally and rectally in macaques, Buffer Gel was found to be 
overall safe and did not affect microflora but did result in epithelial desquamination when used 
rectally [80]. This same study reported that BufferGel did not prevent cervical or rectal 
chlamydial infection.[80]  A safety study found daily administration to the penis of HIV negative 
or HIV-positive men resulted in no serious adverse events which supported progressing to 
efficacy trials in women [81] A safety study in India, Thailand, Malawi, and Zimbabwe asked 
participants to apply BufferGel vaginally twice per day for two weeks [82]. In this trial, 
BufferGel did not disrupt the vaginal epithelial layer and treatment resulted in reduced 
prevalence of bacterial vaginosis from 30% at enrolment to 6% [82]. Unfortunately, BufferGel 
was found to have no effect on HIV transmission to women [83]. 
 While none of the previously mentioned microbicides were effective at preventing HIV 
transmission, their clinical trials highlighted two main issues that need to be considered before 
starting another phase III trial. First, greater attention and more diligence is needed to establish 
microbicide safety before moving on to efficacy trials. This can be addressed with more rigorous 
animal testing and a stricter definition for “well tolerated”. A second issue for microbicide 
research is adherence. Several of the clinical trials summarized here utilized various definitions 
of “adherent” which makes cross comparison between trials difficult. In some cases, the clinical 
trial itself reported low adherence. While some trials such as the MDP-301 made a concerted 
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effort to discover factors affecting adherence (housing conditions), this information should be 
part of every microbicide trial. 
  
Topical Microbicides that Succeeded: What can we learn? 
 The greatest successes have been with antiretroviral based topical microbicides. Of the 
antiretroviral drugs being evaluated, tenofovir based microbicides have shown the greatest 
promise. The CAPRISA004 study evaluated the use of a 1% tenofovir gel to prevent 
transmission of HIV in women who were instructed to apply the gel vaginally within twelve 
hours before sex and to apply a second dose within twelve hours after exposure. Overall 
protection was 39% and this increased to 53% in women with high adherence [40]. This was the 
first clinical trial to demonstrate protection using a microbicide.  
 
Rectal Microbicide Development 
 Based on the CAPRISA004 success, the same drug formulation was used for clinical 
evaluation to prevent rectal HIV transmission, MTN-006. Unfortunately, the formulation 
induced unpredicted side effects, low adherence, and several reported adverse events such as 
diarrhea, nausea, bloating, and pain [84]. It was thought that the side effects were due to the high 
osmolarity of the gel formulation [84]. Results of this trial highlighted the need for development 
of a rectal specific microbicide or ideally a microbicide safe and effective for both vaginal and 
rectal use.  The following clinical trial, MTN-007, was a phase I safety and acceptability trial 
designed to test a new formulation of the 1% tenofovir gel [85]. This new 1% tenofovir gel had a 
reduced osmolarity and did not cause the gastrointestinal side effect reported in MTN-006 [85]. 
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This new, rectal safe gel is currently under investigation for HIV prevention efficacy in the 
MTN-017 clinical trial. 
 Further trials are needed to evaluate dosing strategies and optimal formulations as well as 
potential alternative antiretroviral drug candidates, but the future for microbicide development is 
encouraging. Evaluation of potential antiretroviral drugs with various dosing strategies and 
optimization can be evaluated, pre-clinically, using animal models.   
 
DRUG DISTRIBUTION FOR ORAL VS TOPICAL ANTIRETROVIRAL 
ADMINISTRATION 
 
   PrEP is being evaluated in three main routes of administration 1) oral, 2) topical, and/or 
3) injection. While several antiviral compounds have been investigated, the ones furthest along 
in development are antiretroviral drugs that have been approved for use as ART. Of these drugs, 
tenofovir (TDF or TFV) and emtricitabine have been characterized the most and will be the 
focus of the following sections. 
 
Oral administration of PrEP 
 Currently, ART drugs are prescribed as one or more pills to be taken orally. For the 
purposes of PrEP, an ideal antiretroviral drug candidate should have high penetration in tissues 
where HIV is likely to transmit (cervix, vagina, penis, rectum). Antiretroviral drugs from the 
protease inhibitor class only reach concentrations in the female genital tract that are less than half 
of what is in the plasma [86]. Drugs from the nucleoside reverse transcriptase inhibitors can 
reach two to six fold higher concentrations in mucosal tissues than in plasma [86]. In one study, 
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healthy volunteers took 300mg of Maraviroc twice a day for seven days [87]. The area under the 
drug concentration curves reported a 1.9 fold increase in vaginal tissue and a 2.7 fold increase in 
cervicovaginal fluid compared to blood plasma levels [87]. The integrase inhibitor raltegravir has 
similar levels, multiple dosing resulting in CVF drug concentrations two fold greater than plasma 
[88].  
 As mentioned in a previous section, Truvada has been approved for use as oral PrEP. 
Maraviroc is also under evaluation for both oral and topical PrEP. Therefore, this section will 
describe the reported drug distributions of tenofovir, emtricitabine, and maraviroc. For oral 
administration, tenofovir (TFV) is formulated as a tenofovir disproxyl fumerate (TDF). This 
prodrug form of tenofovir is readily absorbed and disassociates into TFV which is then converted 
to the active drug form within the cell. Under steady-state conditions (regular oral dosing), the 
area under the curve values for TFV are 4 fold higher in vaginal tissue and 33 fold higher in 
rectal tissues than in blood plasma [89]. Under steady-state conditions, emtricitabine reaches 
values 4 fold higher in vaginal tissues and 4.4 fold higher in rectal tissues than in blood plasma 
[89]. Maraviroc reaches 4 fold higher in vaginal tissues and 27 fold higher in rectal tissues [89].  
 Oral administration of antiretroviral drugs does not always result in uniform drug 
distribution to tissues. All three drugs achieved drug concentrations in tissues that are greater 
than in blood plasma Tenofovir and maraviroc attained higher drug concentrations in rectal 
tissue than what is achieved vaginally. Emtricitabine achieves roughly the same concentration in 
both rectal or vaginal mucosal sites. These differences in drug distribution have been considered 
as possible contributions to the different levels of protection measured in iPREX, a MSM 
protection study, and in FEM-PrEP, a heterosexual women protection study . On the other hand, 
Partners PrEP and TDF2 showed protection regardless of participant gender.  
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Topical Administration of PrEP 
 Topically administered PrEP comes in several forms 1) gels, 2) liquids, 3) disovable 
sheets, 4) dissolvable pills/suppositories, 5) vaginal rings, 6) drug containing sponges, 
7)aerosols/nebulizers, 8) powders, and other creative options. For this section, I will focus on the 
forms which have been most frequently studied: gels, liquids, dissolvable solids, and vaginal 
rings. 
 Gels and liquids are popular options due to their ease of use and similarity to sexual 
lubricants and spermicides. They have the potential to release a large amount of drug in a short 
period of time (ideal for peri-coital dosing) or can be designed to slowly release a constant 
amount of drug over longer periods of time (ideal for daily dosing). MTN-001 was a three arm 
clinical trial evaluating the pharmacokinetics of a 1% tenofovir gel applied vaginally (40mg) 
and/or orally administered tenofovir (300mg) [90]. Results from this study reported that serum 
concentrations after vaginal dosing were 56-fold lower than oral dosing but that vaginal tissue 
tenofovir diphosphate was 130-fold higher than in oral dosing [90]. Another curious result was 
that rectal fluid tenofovir concentrations in vaginally dosed participants were higher than 
concentrations measured in the orally dosed arm. This would suggest that vaginal application of 
tenofovir results in some drug migration to the rectum. A similar effect was measured in 
macaques where rectal fluid TFV concentrations were a log lower than vaginal fluids after 
vaginal dosing [91]. RMP-02/MTN-006 evaluated the pharmacokinetics of a 1% tenofovir gel 
applied rectally as compared to orally administered tenofovir [84]. Unfortunately, the gel 
formulation evaluated was not optimized for rectal use and resulted in several adverse events 
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[33]. The pK data gathered from this study demonstrated that topically applied gel resulted in 
maximum tissue drug levels in less than 30 minutes and these levels were 6-10 times greater than 
the maximum levels oral drug administration achieved [84].  
 Dissolvable solids such as sheets and pills have been used previously for distribution of 
contraception (vaginal) or laxatives or opiates (rectal). These devices are designed to release a 
large amount of drug in a short period of time. A study done in pigtail macaques showed that a 
vaginally applied rapidly disintegrating tablet containing tenofovir (10mg/pill) or tenofovir and 
emtricitabine (10mg each) was able to dissolve in less that 30mins with no effect on local 
inflammatory cytokines, pH or microbiota [92]. Investigators found peak vaginal concentration 
around the 10^4-10^5 ng/g tissue (147-571 uM) range at 4hr post dose with sustained levels 
24hrs post dose [92]. Similar levels were reported for FTC. These concentrations are predicted to 
be protective based on previous studies [93, 94]. 
 Vaginal rings are commonly used for contraception and function by the device slowly 
releasing a constant amount of drug for several days (usually a month). Unlike gels and 
dissolvable solids, drug releasing rings may not be practical for rectal use. While vaginal rings 
designed to elute antiretroviral drugs have not been tried in humans, they have shown very 
promising results in macaque models [95]. Smith et.al. tested TDF-eluting vaginal rings in 
macaques [95]. Each ring eluted TDF continuously for 28 days and was then replaced with a new 
ring for a total of 4 months of drug/ring exposure. After 16 weekly vaginal exposures to 
SHIV162p3, all of the animals with TDF rings remained non-infected while 11 out of 12 control 
animals became infected [95]. Similar to the pharmacokinetic results seen in gels and dissolving 
solids, the rings generated high cervical fluid levels of tenofovir (mean 1.8x10^5 ng/mL) [95]. 
Preliminary acceptability trials using placebo rings in Africa reported that women found vaginal 
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rings to be highly acceptable once initial concerns such as the ring “getting lost inside the body” 
(20% of participants) were addressed [96]. 
 In general, topical administration of antiretroviral drugs results in highest drug levels 
where the PrEP is administered. Depending on adsorption, some drugs applied topically can be 
detected in plasma and other tissues but these levels may not offer protection. There are many 
options for topical administration of PrEP which may improve adherence. 
 
Long acting injections for PrEP 
 Long-acting injections of antiretroviral drugs have great potential for both ART and 
PrEP. In theory, a patient would be able to receive an injection of drugs once a month or once a 
quarter instead of taking daily pills. This technology has been safely used for administration of 
common methods of birth control, Depo-Provera and DMPA, in many sub Saharan countries 
where HIV is most prevalent [97]. In terms of PrEP, long acting injections could greatly improve 
adherence by providing a consistent, systemic level of drug release over an extended period of 
time [98-100]. At this time, these anti-HIV injections have only been tested using animal models 
but the results are very encouraging [99-101]. In a recent study published in Science, a novel 
long-acting injectable integrase inhibitor was administered to macaques at two time points 4 
weeks apart [101]. These animals were challenged weekly for 8 weeks and remained non-
infected [101]. The same study also did an experiment were animals were give a single drug 
infection followed by weekly exposures to virus until the animals became infected [101]. The 
animals remained protected from infection until plasma drug levels dropped several weeks after 
initial drug administration [101]. 
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Topical vs Oral PrEP 
 Topically administered PrEP can achieve higher tissue drug levels than has been achieved 
with oral PrE . Topically administered PrEP is most effective at the site of application. 
Formulations for topically administered PrEP need to be designed to function in both vaginal and 
rectal compartments. 
  Drug formulations for oral PrEP is much simpler since the oral preparations used for 
ART already have passed safety evaluations and gained FDA approval. Orally administered 
PrEP can provide systemic distribution of drugs which may result in HIV protection from 
multiple routes of exposure including from injection drug use.  
 Overall, it is unknown what concentration of drug is needed for protection at the different 
sites of mucosal exposure. More detailed studies will be needed to determine what the minimum 
amount of drug presence is needed to provide significant protection. The only assumption that 
can be inferred is that “more is better”. In other words, we know that a complete absence of drug 
presence will not provide protection. On the other hand, several clinical trials correlate drug 
presence with protection.  
 Ideally, topical, oral and injectable forms of PrEP should be developed and approved for 
use. Having multiple options available for PrEP may encourage adherence to use at least one if 
not more methods to prevent HIV transmission. 
 
DRUG SUSCEPTIBILITY AND RESISTANCE 
  “Drug susceptibility” refers to the amount of drug needed to suppress viral replication in 
vitro. Drug susceptibility testing is usually done by culturing a fixed viral inoculum with a serial 
dilution of a viral inhibitor and measuring some output signal for viral replication (p24, copy 
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number, fluorescent indicator, etc). The concentration of inhibitor needed to prevent 50% of in 
vitro replication is the IC50. The choice of culture cells, viral inoculum, indicator for viral 
replication, and other parameters can result in different IC50 values unique to that particular assay 
and to the specific viral inhibitor used. Therefore, comparisons of IC50 values can only be done if 
the assay used to generate them are similar.   
 While drug susceptibility testing cannot be used to predict the amount of drug needed for 
in vivo treatment, it is a powerful tool for evaluating relative drug susceptibilities for genetically 
different viral strains.  These differences in susceptibilities (often expressed as fold change or 
“shift” in IC50) have been used to determine which genetic mutations contribute to drug 
resistance. For example, the K65R mutation in HIV’s reverse transcriptase protein will result in a 
2 to 4 fold increase in tenofovir IC50. This means, a virus containing the K65R mutation is 
expected to require 2 to 4 times more drug to reach the same suppression seen in a virus with the 
original lysine residue. It should be noted that drug resistance is usually referring to fold changes 
in IC50 as a result of one or a few mutations difference from an original “wild type” sequence.  
This is different from the natural variation in IC50 values observed between strains of HIV who 
would each be considered “wild type”. This concept will be explored more in the following 
sections. 
 
Drug Resistance Based on Genotype 
 As mentioned before, HIV has an incredible amount of natural diversity and variation in 
genetic sequence which makes defining a “wild type” sequence difficult.  Fortunately, advances 
in gene sequencing technology and the creation of large sequence databases such as those 
provided by the NIH and the Stanford Drug Resistance Database and have allowed researchers to 
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compile phenotypic information as they relate to specific genotypic sequences. Not only have 
consensus sequences been developed for all major HIV clades, specific variations from these 
consensus sequences have been identified as contributing to drug resistant phenotypes. Using the 
same example from the previous section, the K65R mutation represents a single amino acid 
variation from consensus sequence that has been shown to decrease susceptibility to tenofovir. 
Therefore, sequence data obtained from patients can be compared to the consensus (wild type) 
sequences available for each HIV clade.  
 Variations between patient sequence and wild type sequence, also known as 
polymorphisms, are common but not all variations contribute to drug resistance. To simplify 
matters, the WHO and the IAS publish yearly updates listing which mutations are considered to 
be “drug resistance” mutations. It should be noted thought that variation in viral polymorphisms 
can often reduce or increase the effect of a known drug resistance mutation [102].  
 
De novo drug resistance and replicative fitness 
 HIV can develop resistance to all drugs currently available for treatment [103, 104]. The 
mechanism for development drug resistance lies in the high error rate of HIV’s reverse 
transcriptase. Each round of viral replication can result in one or more nucleotide 
misincorperations. Some misincorperations will result in a defective viral genome and the 
progeny virus will be non-infectious or have a reduced replicative capacity. These viral lineages 
will be rapidly out competed by viral lineages that do not have a defect [105, 106]. Other 
nucleotide mutations may result in changes of amino acid sequence that confer resistance to 
antiviral drugs. These mutations are rare but can occur at any time resulting in resistance to any 
antiretroviral drug [107]. In very rare cases, a single round of replication can result in 
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accumulation of more than one drug resistance mutation. In the absence of antiretroviral drugs, 
drug resistant viral genomes do not have an advantage and are therefore unable to out compete 
the general viral population. In the presence of antiviral drugs, the relative fitness of drug 
resistant virus is greater than that for drug susceptible virus and the resistant virus will be able to 
out compete and dominate the infection [105, 106, 108-111]. Therefore, the use of antiretroviral 
drugs does not create drug resistance mutations in HIV. The mutations occur randomly and 
selective pressure provided by the presence of an antiretroviral drug is what allows a drug 
resistant HIV to dominate the infection. 
 To prevent the out growth of drug resistant HIV, current ART therapies consist of a 
cocktail of multiple drugs with different classes of action. While it is possible to acquire a drug 
resistance mutation easily, this mutation is usually only effective against one drug or one class of 
drugs. For example, the K65R mutation is effective against the NRTI drug tenofovir, but the 
mutation is not effective against any of the protease inhibitors. Therefore, even if a patient has a 
viral population with a tenofovir resistance mutation, this population will be suppressed by one 
of the other drugs being prescribed. It is possible, but less-likely, for a single round of viral 
replication to result in two drug resistance mutations. For this reason, patients are prescribed at 
least three different antiretroviral drugs. The likely hood of a single round of viral replication 
resulting in acquisition of three drug resistance mutations is extremely low. The low “likelihood” 
of developing drug resistance is often referred to as the genetic barrier to resistance.  Several 
studies have been tried to quantify the genetic barrier to resistance [112-114]. Factors that affect 
the likelihood of developing a drug resistance mutation include what type of mutation is needed 
to induce the amino acid change and how many nucleotide mutations are needed [107, 115, 116]. 
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Polymorphisms at other nucleotide locations may also affect the selection of drug resistance 
mutations [102, 117-119].  
 
Transmitted Drug Resistance 
 For this section, “drug resistant virus” will be defined as HIV with at least one of the 
genetic mutations listed on the WHO or IAS drug resistance surveillance reports [103, 120]. 
Drug-resistant viruses can be transmitted from person to person [121-124] . The inherent ability 
of replicating HIV to revert to a drug sensitive genotype in the absence of drug pressure makes it 
difficult to study in patients especially if: (1) the time/duration/route of infection are unknown, 
(2) there is no way to prove ART naïve status, and (3) the HIV sequence in the infecting partner 
is unknown.  Despite these difficulties, genotypic analysis of ART naïve patients has provided 
evidence that drug resistant HIV-1 is being transmitted and can result in treatment failure [125-
131].  
 As mentioned before, drug resistant HIV can only be selected for by the presence of 
antiretroviral drugs. Proper prescription and adherence to ART can prevent out growth and 
spread of drug resistant HIV. Therefore, it is no surprise that the regions with greatest 
transmitted drug resistance are areas where antiretroviral drugs have only recently been made 
available and adherence is not consistent. For example, the past decade has seen a dramatic 
increase in ART availability in resource limited areas in eastern and southern regions in Africa. 
along with this increase in ART, there has been an increase in transmitted drug resistant HIV 
[132].  
 The frequency of transmitted drug resistance varies depending on the specific drug 
resistance mutation in question, that mutation’s predicted effect on replicative fitness, and what 
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antiretroviral drugs are used in the region where transmission is occurring. For example, the most 
commonly transmitted drug resistance mutations tend to be NRTI or NNRTI mutations due to 
the high use of these drugs for ART [103, 120, 123, 124, 128, 129, 132]. Of these mutations, 
K65R and M184V are of specific interest since they confer resistance to the two drugs most 
heavily investigated for PrEP (tenofovir and emitracitabine).  
   
Effect of PrEP on Transmitted Drug Resistance 
 The use of first line therapy drugs for both protection and treatment has raised concerns 
that there will be an increase in transmission of drug resistant HIV. An example of this would be 
a patient who is taking Truvada as a PrEP but who experiences a break through infection and 
continues to administer Truvada. Truvada is a dual drug formulation that may not be sufficient to 
fully suppress HIV infection and the end result is rapid de novo development of drug resistant 
HIV which can then be passed to future individuals.  This exact scenario has occurred in at least 
one of the oral PrEP clinical trials [22]. While this is a real concern for individuals, it may not 
result in an increase in transmitted drug resistance at the population level. 
  In 2010, Supervie et. al. published a model which predict that PrEP would reduce the 
prevalence of drug resistant HIV [133]. This reduction is based on two main predictions. First, 
use of PrEP will reduce the number of HIV infected individuals, which will inturn reduce the 
opportunity for de novo drug resistant HIV to develop. If there are fewer people who develop 
drug reistance, then there are fewer opportunities for drug resistant HIV to be transmitted. 
Supervie finds this to be true even if a percentage of individuals on PrEP develop resistance due 
to undetected breakthrough infection. The second main prediction assumes that transmission of 
drug resistant HIV will still be inhibited (at least by some small degree) by PrEP. This prediction 
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is based on the fact that “drug resistance” is merely a shift in drug susceptibility resulting in only 
a reduction in drug efficacy rather than a complete immunity to drug effect. 
 Most models assume that the PrEP being used is an orally administered antiretroviral 
drug. As described in the previous section, drug distribution patterns are very different between 
oral and topical administration. How these differences in drug distribution can affect the de novo 
or transmission of drug resistance in a PrEP/microbicide situation will require more study. There 
is as of yet, no evidence that topically administered antiretroviral PrEP can result in generation of 
drug resistant HIV. Animal studies could be very useful to evaluate the safety of topical PrEP in 
infected individuals. 
 
MICROBIOTA EFFECT ON HIV TRANSMISSION  
 
 The term “microbiota” refers to a collection of microbial species while the “microbiome” 
specifically refers to the genetics of those microbial species. There is no realistic way to measure 
the “microbiota” since most commensal microbiota cannot be cultured and microscopic 
classification of every species in an individual’s microbiota would take decades, but there are 
ways to evaluate the “microbiome” through high throughput, deep sequencing [134]. Deep 
sequencing platforms such as the Illumina series and 454 Life Sciences systems allow 
researchers to determine the composition of a sample’s entire microbiome down to the single 
genome level [135]. These technologies have been used to highlight the importance and 
involvement of the human microbiome in wellness and disease. 
  Highly competitive environments such as the gastro-intestinal tract and male and female 
reproductive tract provide sites for complex microevolution and extensive co-dependence 
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networks for the microbiota present [136]. The composition of the microbiome can fluctuate 
greatly and in a short period of time [137-139]. The intestinal tract and reproductive tract of 
mammals are initially colonized by microbiota from their mother during birth, nursing, and 
interactions with the environment [140-142]. Through life, the microbiota of the intestinal tract is 
greatly influenced by host diet [143]. The microbiota of the female and male reproductive tracts 
are greatly influenced by sexual activity, changes in hormones, as well as cleaning practices 
[144-146].  Biomedical interventions such as antibiotic treatments, use of diuretics, use of 
laxatives, anti fungal medications, use of drug based birth controls, and circumcision all have an 
impact on microbiota composition [147-149]. Majority of the changes to the microbiome go un-
noticed by the host organisms, but occasionally changes can result in symptoms. Changes in 
intestinal microbiome have been associated with irritable bowel disorders such as colitis and 
Crohn’s disease [143, 150]. Patients using large amounts of antibiotics may see rapid out growth 
of Clostrida difficile, which is best treated by re-introduction of commensal organisms who then 
compete with C. difficile for resources [148, 151-153]. Changes in vaginal microbiome can result 
in a condition known as bacterial vaginosis or yeast infection [154-156].  
  
Microbiome may affect HIV transmission and pathogenesis 
 Acquisition and pathogenesis of sexually transmitted diseases, such as HIV,  may be 
enhanced or limited by microbiota at the site of mucosal exposure [145, 154, 155, 157]. 
Specifically, concurrent symptomatic infection of an STD with inflammation, rash, ulcers, or 
other breaches in the mucosa enhance the probability of HIV transmission [158]. On the other 
hand, far less is known about the effect of commensal microbiota, but there is a building body of 
evidence supporting the theory that commensal microbiota also plays a role in HIV acquisition. 
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 Given the inherent tendency for commensal microbiota to rapidly fluctuate in 
composition within the same individual, studies to evaluate microbial contribution to HIV 
transmission in humans are often difficult and can only estimate the microbial composition at the 
estimated time of HIV transmission. Despite this large difficulty, commensal microbiota has 
been indicated as affecting sexual HIV transmission in several studies [145, 159-162] . A study 
done in Thailand looked at both HIV negative and HIV positive sex workers [162]. This study 
found a correlation between vaginosis and HIV infection but could not determine which 
condition came first. A different study of 657 HIV negative, female sex workers in Kenya 
examined the relationship between vaginal colonization with lactobacilli, bacterial vaginosis, and 
poteintial acquisition of HIV [161]. Women who did not vaginal lactobacillus species had an 
increased risk of acquiring HIV and gonorrhea. Women who had abnormal vaginal flora had an 
increased risk of both HIV and Trichomonas infection. In general, bacterial vaginosis is 
presumed to increase acquisition of HIV while lacto bacilli are presumed to decrease acquisition 
of HIV. 
 The majority of HIV transmission studies focused on the vaginal econiche. Few studies 
have been done evaluating the effect of microbiota on rectal HIV transmission and the results 
were inconclusive [163]. In 1994, Law et. al. published the results of a study evaluating 144 
MSM subjects [163]. The study found a correlation between HIV infection and detection of 
spirochaets in rectal biopsies but could not determine if infection was cause or effect [163].  
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ANIMAL MODELS TO TEST HIV PREVENTION 
 
SIV/Non-human Primate Models 
 The safety and efficacy of antiretroviral drugs can be evaluated in animal models before 
their use in human clinical trials. HIV represents a unique difficulty due to its limited tropism. In 
1986 the etiological agent for AIDS was isolated and its discovery gave scientists the ability to 
start empirical transmission studies. One year after the discovery of HIV-1, chimpanzees were 
utilized as a model to study HIV-1 transmission because they are the only animals, other than 
humans, naturally capable of sustaining an HIV infection. Chimpanzee studies improved our 
knowledge of HIV-1 transmission and pathogenesis but had noticeable differences from human 
pathogenesis including an absence in cytotoxic T-cell lymphocyte response to HIV 
infection[164-167] . In addition, many regions consider chimpanzees to be an endangered 
species which greatly restricts their availability for research. Therefore, scientists turned to 
alternative models to represent HIV-1 transmission; SIV and SHIV. SIV is the most similar virus 
to HIV. Therefore many of the aspects of SIV infection in simians could provide insight on HIV 
infection in human.  
 Over 40 species of African monkeys are endemically infected with a species specific SIV 
[168].  Of these speces, the sooty mangabey (SMs) and the African green monkey (AGM) are 
considered to be natural SIV hosts while other species such as the rhesus macaque (RM) are not 
natural hosts. Natural SIV hosts do not typically develop AIDS despite high viral replication 
[169-174]. These animal models do not develop AIDS, have high viral replication, maintain 
healthy levels of peripheral CD4
+
 T-cells, do not have mucosal immune dysfunction, do not 
develop chronic immune activation, and do not often pass SIV infection by MTCT [169-174]. In 
contrast, non-natural hosts such as the rhesus macaque (RM) respond to SIV infection similar to 
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the way how humans respond to HIV infection. SIV-infected RMs will progress to AIDS, lose 
peripheral CD4
+
 T-cells, develop mucosal immune dysfunction, have increased microbial 
translocation, develop chronic immune activation, and can readily pass SIV through MTCT 
replication [169-174]. These dramatic differences in how host species respond to SIV infection 
has led to great insights into understanding the human response to HIV infection [168]. The 
mechanisms by which natural hosts limit the effects of SIV infection may be useful for 
developing novel HIV therapeutic strategies. 
 To further enhance the usefulness of the non-human primate models, investigators have 
developed viral strains that mix the genes of SIV with HIV to create chimera SHIVs. Multiple 
SHIVs have been created with varying mixtures of SIV and HIV genes. In general, SHIVs must 
contain a SIV env gene to enable the virus to infect simian cells. SHIVs have been used to 
evaluate the species specificity of viral proteins such as vif and vpu. 
 
Humanized Mouse Models 
 Twenty years after the discovery of HIV, a novel model became available for 
transmission studies: the humanized mouse. Initially, this model was limited to genetically 
immune deficient mice (SCID and Bg/Nu/XID) who received a human peripheral blood 
transplantation [175-177]. Then, humanized mice were improved by the availability of different 
genetic backgrounds and human cell/tissue engraftment techniques. The following work was 
done utilizing the bone marrow/liver/thymus (BLT) humanized mouse model. This humanized 
mouse model is made with NOD/SCID IL-2 receptor gamma
 
chain knockout mice that have been 
irradiated, implanted with human thymus and liver tissue under the kidney capsule, and received 
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a bone marrow transplant with autologous hematopoietic stem cells. BLT mice harbor a de novo 
generated human immune system distributed throughout each animal [178-200]. 
 BLT mice recapitulate nearly all of the features of HIV transmission and infection. BLT 
mice are capable of mucosal transmission of HV via vaginal, rectal, or oral routes and sustain 
HIV infection for the duration of their lifespan [201-205]. Studies utilizing these animals have 
demonstrated the presence of a viral reservoir much like that of human HIV patients [179]. HIV-
infected mice respond to ART and can develop drug resistant HIV infections when ART is given 
in suboptimal doses [179, 206]. Therefore, BLT mice provide an excellent small animal model 
for testing the efficacy of HIV transmission prevention strategies where enough animals can be 
used to generate statistically meaningful results. 
 Previously, BLT mice were used to test the protective effect of systemically administered 
antiretroviral drugs to prevent HIV transmission after rectal or intravenous exposure [184]. 
Briefly, BLT humanized mice were administered daily FTC/TFV for seven consecutive days. On 
the third day, mice were exposed rectally or intravenously to HIV-1. Mice receiving PrEP were 
completely protected from rectal transmission of HIV and had only one breakthrough infection 
(1 of 8 mice) when exposed intravenously [184]. The BLT mouse model has also been used to 
recapitulate the human clinical trial CAPRISA004. In this clinical trial, participants were 
instructed to apply a 1% tenofovir gel vaginally before and after coitus [40, 93]. The human 
clinical trial found topically applied tenofovir to be protective against vaginal HIV. The same 
topical tenofovir PrEP was found to be protective utilizing the humanized BLT model [180]. 
Within the same humanized mouse study, six additional topical microbicide candidates were 
successfully evaluated [180] . Of the six topical microbicides, four were found protecteive 1) 
C52L, a C-peptide fusion inhibitor at 500uM concentration,  2) topical combination of 16.5uM  
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TDF and 28uM FTC , 3) C5A, a membrane-disrupting amphipathic peptide inhibitor at 200uM 
concentration, and 4) PIE 12-Trimer, a trimeric D-peptide fusion inhibitor at 100uM 
concentration. Of the six topical microbicides tested, a thioester compound (TC247) at 500uM 
concentration one was found to only offer partial protection (50%) and a small molecule Rac 
inhibitor (NSC23766,Calbiochem) at 10mM concentration was found to have no protection at 
all. 
 Humanized mice have also been useful for evaluating effective ART for HIV treatment. 
In one study, BLT mice were infected with HIV and treated with daily injections of ART 
(200mg/kg body weight FTC, 208mg/kg TDF, and 80mg/kg RAL) resulting in viral load 
suppression to undetectable levels within two weeks [207]. Interruption o f ART resulted in viral 
rebound [208]. 
 In summary, humanized mice provide a reliable small animal model to evaluate novel 
HIV transmission interventions. They are susceptible to HIV transmission through vaginal, 
rectal, wound/intravenous, and/or oral exposure. Previous studies with humanized mice have 
shown them capable of evaluating both systemic and topical PrEP strategies. 
 
 
SIGNIFICANCE AND OBJECTIVES 
  
 The only way to stem the HIV/AIDS epidemic is to prevent viral transmission to 
uninfected individuals. In the past, behavior modification strategies, HIV testing, encouraging 
condom usage, and discouraging sharing needles have all helped to prevent the spread of HIV 
along with other pathogens. Recommendations such as Option B or Option B+ have greatly 
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reduced mother-to-child transmission rates in regions with access to antiretroviral drugs. To date, 
sexual transmission of HIV is the greatest driver of the HIV/AIDS epidemic. Consistent condom 
usage and male circumcision have both proven to be effective at reducing HIV transmission but 
require the penetrating partner to consent and accept these practices. 
 Topically applied interventions or microbicides, on the other hand, may have higher 
acceptability due to their similarity to already available sexual products/lubricants, their possible 
availability over-the-counter, and local administration of product may not result in as many side 
effects or complications. Therefore, the main objective of my dissertation is to explore factors 
affecting mucosal transmission of HIV and evaluate forms of HIV prevention that are applied 
topically. 
 Topically applied PrEP/microbicides designed to prevent HIV transmission have been 
and are currently being tested for efficacy is multiple clinical trials. Among these interventions, 
antiretroviral drugs applied topically for PrEP is the furthest advanced through clinical trials. 
Therefore, part of my dissertation work evaluated the efficacy of topically applied antiretroviral 
drugs from two different drug classes to prevent HIV transmission. The use of antiretroviral 
drugs for prevention as well as treatment has raised concerns about transmitted drug resistant 
HIV. To address this I demonstrated how drug resistant HIV may be transmitted albeit 
inefficiently. Topically applied interventions that are not antiretroviral based are also under 
investigation. Among these are interventions aimed at affecting the commensal flora at the site of 
exposure to prevent mucosal HIV transmission. To evaluate the effect of commensal flora on 
HIV transmission, I developed a humanized mouse model with a human associated microbiome. 
Utilizing these mice, it was determined that commensal microbiota composition does affect HIV 
transmission.  
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 Overall, by using humanized mice as an experimental platform, we expanded our 
knowledge of mucosal HIV transmission prevention strategies. Knowledge gained from this 
work supports the development of tenofovir and/or Maraviroc based PrEP for human use, 
reduces some of the concern of transmitted tenofovir resistant HIV, and provides powerful 
empirical evidence supporting microbial involvement in HIV transmission.  
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CHAPTER II – RECTAL TRANSMISSION OF TRANSMITTED/FOUNDER HIV-1 IS 
EFFICIENTLY PREVENTED BY TOPICAL 1% TENOFOVIR IN BLT HUMANIZED 
MICE
1 
 
 
AUTHOR SUMMARY 
 
 Rectal microbicides are being developed to prevent new HIV infections in both men and 
women. We focused our in vivo preclinical efficacy study on rectally-applied tenofovir. BLT 
humanized mice (n = 43) were rectally inoculated with either the primary isolate HIV-1JRCSF or 
the MSM-derived transmitted/founder (T/F) virus HIV-1THRO within 30 minutes following 
treatment with topical 1% tenofovir or vehicle. Under our experimental conditions, in the 
absence of drug treatment we observed 50% and 60% rectal transmission by HIV-1JRCSF and 
HIV-1THRO, respectively. Topical tenofovir reduced rectal transmission to 8% (1/12; log rank p 
= 0.03) for HIV-1JRCSF and 0% (0/6; log rank p = 0.02) for HIV-1THRO. This is the first 
demonstration that a human T/F virus rectally infects humanized mice and that its transmission 
can be efficiently blocked by rectally applied 1% tenofovir. These results obtained in BLT mice, 
along with recent ex vivo, Phase 1 trial and non-human primate reports, provide supportive 
evidence to promote the development of tenofovir-based rectal microbicides. 
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is a follows: M.L. Chateau, P.W. Denton, M.D. Swanson, I. McGowan, and J.V. Garcia. Rectal 
transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in 
BLT humanized mice. PLoS One. 2013;8(3):e60024. 
 
Author contributions are as follows:  conceived and designed the experiments, MC MS; IM, VG 
performed the experiments, MC ; analyzed the data, MC; wrote the paper, MC, PD, MS, IM, VG 
 
47 
 
INTRODUCTION 
 
Efficacious biomedical HIV prevention interventions could dramatically reduce the 
number of new HIV infections globally [209-216]. Microbicides (also referred to as topical pre-
exposure prophylaxis [topical PrEP]) represent one of several classes (e.g. oral PrEP, treatment-
as-prevention) of such interventions currently being developed [34, 217-222]. There are multiple 
reasons why microbicides are attractive as tools for HIV prevention: (i) local administration of 
an antiretroviral gel at the site of exposure will result in higher drug levels at the intended 
anatomical location than can be achieved using oral PrEP [28, 31-33] while reducing the 
likelihood of experiencing systemic dosing-associated toxicities [33, 34]; (ii) the reduced toxicity 
associated with topical microbicides is expected to increase adherence [35]; (iii) microbicides are 
user controlled [28]; (iv) microbicides are predicted to be cost-effective [29, 30]; (v) topical 
microbicides can be developed with combinations of viral inhibitors [36]; (vi) an ideal 
microbicide would be safe and effective in both rectal and vaginal compartments [37-39]; and 
(vii) antiviral microbicides may also protect against viruses other than HIV (e.g. herpes simplex) 
[40, 41]. 
All microbicide efficacy clinical trials to date have tested the prevention of vaginal HIV 
transmission [35, 56, 75, 78, 213, 217, 223-227]. However, an important driver of the epidemic 
in both men and women is HIV transmission resulting from anal intercourse [228-235] such that 
rectal microbicide development is also required [35, 53, 94, 236-238]. Proof of concept that 
administration of an antiretroviral gel rectally can prevent transmission of SIV/SHIV has been 
demonstrated for tenofovir [239] and MIV-150 [240]. Tenofovir, UC781, and nonoxynol-9 have 
been tested for safety and acceptability in Phase 1 rectal microbicide clinical trials [32, 33, 55, 
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241]. Of these three candidates, only tenofovir 1% gel has advanced to Phase 2 rectal testing and 
could be considered for Phase 3 efficacy trials in the future [35]. Therefore, our in vivo 
preclinical efficacy study in bone marrow-liver-thymus (BLT) humanized mice was designed to 
determine the efficacy of topical tenofovir for the prevention of rectal HIV-1 transmission. 
BLT mice are the experimental platform of choice for this study for several reasons. For 
example, BLT mice harbor a de novo generated human immune system distributed throughout 
each animal [178-200]. In the context of this study, an important characteristic of BLT mice is 
their susceptibility to rectal HIV-1 transmission [184, 187] due to the presence of human CD4
+
 T 
cells, macrophages and dendritic cells found throughout BLT mouse intestines, including the 
rectum [178, 187], previously both topical [180] and systemic [183, 184] HIV prevention 
interventions have been extensively tested in BLT mice for their ability to block vaginal 
transmission of HIV-1. The results obtained from these studies were highly predictive of the 
clinical trial outcomes [180, 183, 184, 217, 221, 242]. 
 An important and novel aspect of this study is the use of a MSM-derived 
transmitted/founder (T/F) virus [243]. Typically only one or a few virions (defined as the T/F 
viruses) are responsible for a mucosal transmission event in humans making T/F viruses 
physiological relevant for in vivo efficacy studies of HIV prevention interventions [244, 245]. 
BLT mice were treated rectally with topical 1% tenofovir and then rectally inoculated with HIV-
1JRCSF, a well characterized low passage primary isolate, or the T/F virus HIV-1THRO. We found 
that rectal transmission of both viruses was efficiently prevented by topical tenofovir. 
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RESULTS 
 
 Human PBMC reconstitution of BLT mouse pre-exposure.  
This study was designed to determine the in vivo efficacy of topical tenofovir for the 
prevention of rectal HIV-1 transmission. Prior to HIV-1 exposure of the BLT mice, their 
peripheral blood was characterized by flow cytometry to confirm reconstitution with human 
cells. All BLT mice used herein (n=43) had high peripheral blood reconstitution levels of human 
lymphoid (CD45
+
) cells (67% mean ± 17 SD) and human CD4
+
 T cells (80% mean ± 6 SD) 
(Summarized in Tables 1 and 2). 
 
Topical tenofovir prevents rectal HIV-1JRCSF transmission.  
A total of 29 mice were exposed to HIV-1JRCSF, a CCR5-tropic virus that has been well 
characterized for its mucosal infection of BLT mice [180, 181, 183, 184, 187, 199, 200]. 
Seventeen mice received vehicle and 12 mice received topical tenofovir (Figure 2; Table 1). 
Following viral exposure, peripheral blood from the BLT mice was sampled weekly for the 
presence of HIV-1 RNA (Figure 1). Eight of the 17 mice in the control arm of the experiment 
were infected as determined by the presence of viral RNA in plasma (Figure 2A). In contrast, 11 
of 12 topical tenofovir treated mice were consistently negative for the presence of plasma viral 
RNA (Figure 2A). One tenofovir treated mouse was found to have a ‘breakthrough’ infection 
with readily detectable plasma viral RNA (Figure 2A). No tenofovir resistant mutations from this 
breakthrough virus were identified when the entire reverse transcriptase gene was sequenced. 
Over the course of this experiment, we also monitored the levels of CD4
+
 T cells in peripheral 
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blood. The breakthrough infection mouse and the infected vehicle control mice had peripheral 
blood CD4
+
 T cell levels similar to the HIV-1 negative mice (Figure 2B). 
Prior to defining topical tenofovir treated BLT mice as protected from rectal HIV-1 
transmission, we tested tissues harvested from these mice for the presence of cell-associated 
HIV-1 DNA. All mice without plasma viral RNA were also found to be negative for viral DNA 
in all tissues evaluated (e.g. bone marrow, spleen, human thymic organoid and lymph nodes) 
confirming the lack of HIV-1 transmission in these animals (Figure 2C; Table 1). The HIV status 
and time to plasma viremia were then combined to generate a Kaplan-Meier plot of the 
protection from rectal HIV transmission provided by topical tenofovir (Figure 3). Log rank 
analysis (p=0.03) confirmed that topical tenofovir prevents rectal HIV-1JRCSF transmission in 
BLT mice. 
 
Rectal transmission of transmitted/founder HIV-1THRO is prevented by topical tenofovir. 
 HIV-1THRO is a CCR5-topic, MSM-derived T/F virus [243]. A total of 14 BLT mice were 
exposed rectally to HIV-1THRO (Figure 4). Eight mice received vehicle and six mice received 
tenofovir. Five of the mice receiving vehicle were infected as determined by the presence of 
plasma virus RNA (Figure 4A). In contrast, none of the tenofovir treated BLT mice (0/6) 
exposed rectally to HIV-1THRO exhibited plasma viremia (Figure 4A). In addition to plasma 
viremia, we also monitored the levels of human CD4
+
 T cells in the peripheral blood of all the 
HIV-1THRO exposed mice. The levels of human CD4
+
 T cells in the infected mice did not change 
throughout the course of infection (Figure 4B). 
To confirm the lack of HIV-1 infection of the tenofovir treated mice we used real time 
PCR to determine the presence of cell-associated HIV-1 DNA in tissues obtained from these 
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mice. None of the mice treated with tenofovir had detectable levels of viral DNA in any of the 
tissues examined (Figure 4C; Table 2). In contrast, the presence of viral DNA in tissues from 
infected animals was readily confirmed (Figure 4C; Table 2). Log rank analysis of these results 
presented in a Kaplan-Meier plot (Figure 5) revealed that topical tenofovir administered prior to 
exposure to BLT mice prevents rectal transmission of the physiologically relevant T/F virus, 
HIV-1THRO (p=0.02).  
 
 
DISCUSSION 
 
Mucosal infection after sexual intercourse is the most common route of HIV-1 
transmission worldwide which makes the cervicovaginal and rectal mucosa the two most 
important anatomical sites for viral exposure [246]. Receptive anal intercourse has the highest 
risk of HIV-1 infection and accounts for most new infections in the US [247, 248]. Nevertheless, 
the vast majority of past and ongoing clinical trials for HIV prevention using topical 
microbicides have focused on preventing vaginal HIV-1 acquisition [35, 56, 75, 78, 213, 217, 
223-227]. The formulation of tenofovir 1% gel used in the RMP-02/MTN-006 Phase 1 rectal 
safety study was the same formulation used vaginally in the CAPRISA 004 trial [33, 217]. 
Unfortunately, there was a significant increase in gastrointestinal adverse events seen in the 
RMP-02/MTN-006 study, possibly due to the hyperosmolar nature of the gel [33, 35]. We 
therefore elected to evaluate the efficacy of tenofovir directly, in the absence of any type of gel, 
to make a clear determination of the potential efficacy of tenofovir for the prevention of rectal 
HIV transmission. Our study supports the choice of tenofovir as an appropriate active 
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pharmaceutical ingredient around which a specifically engineered microbicide can be designed 
for rectal [32, 33, 35] or dual compartment use [38, 39]. 
Our goal was to evaluate the in vivo efficacy of a viable candidate for inclusion into a 
rectal microbicide to prevent HIV-1 acquisition. We focused on rectal HIV transmission because 
this route of virus spread continues to be a major contributor to the number of men and women 
becoming infected with HIV [228-234]. We chose a topical intervention because of the many 
potential benefits associated with this drug delivery route [28-30, 33-41]. BLT mice were chosen 
as the experimental platform for this evaluation because previous studies have shown that FDA 
approved drugs prevent mucosal HIV transmission of the human primary virus isolate HIV-
1JRCSF in this model [180, 183, 184]. Here when BLT mice were pretreated with topical tenofovir 
(or vehicle) and then rectally exposed to HIV-1JRCSF, we found that topical tenofovir efficiently 
prevents rectal transmission of HIV-1JRCSF (Figures 2 and 3; Table 1). 
To extend and expand on this observation we also evaluated the protective effect of 
tenofovir using a second virus, HIV-1THRO. HIV-1THRO is a MSM-derived T/F virus and therefore 
its evaluation in the context of rectal transmission is of significant relevance [243]. T/F viruses 
represent the one or few founder viruses that undergo amplification in local T cells and 
subsequent systemic dissemination after mucosal exposure [243-245, 249]. These T/F viruses 
use CCR5 as a coreceptor for entry and replicate poorly in monocyte/ macrophages relative to T 
cells [243]. Despite their intrinsic relevance, T/F viruses have not been previously used for in 
vivo transmission studies in animal models. We found that HIV-1THRO transmits rectally in BLT 
mice and that its transmission can be efficiently prevented by pretreatment with rectally applied 
tenofovir (Figures 4 and 5; Table 2). 
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Analysis of the data from two HIV-1 isolates indicates that 1 of 18 BLT mice became 
infected despite treatment with topical 1% tenofovir prior to rectal HIV-1 exposure, while 13 of 
25 vehicle treated BLT mice became infected (p=0.002 Fisher’s exact test) (Tables 1 and 2). In 
an in vivo study using non-human primates (NHP), 2 of 6 macaques became infected despite 
treatment with topical 1% tenofovir 15 minutes prior to rectal SIV exposure, while 3 of 4 vehicle 
treated macaques became infected [239]. The conclusion reached by the authors of the macaque 
study and our conclusion of the study presented here are that topical tenofovir can inhibit rectal 
transmission of SIV [239], primary HIV-1 (Figure 3) and T/F HIV-1 (Figure 5). 
Topical microbicides are of significant interest in HIV prevention because they achieve 
high local drug concentrations capable of preventing HIV transmission with reduced risk for 
toxicity [28, 33, 34]. The in vivo preclinical efficacy data presented here together with previous 
data from NHP [239] show that topical tenofovir can efficiently block rectal transmission. The 
incorporation of a physiologically relevant T/F HIV-1 into this study of rectal HIV prevention 
increases its translational value. The results presented here show the importance of animal 
models for the evaluation of HIV-1 prevention strategies and demonstrate the potential for 
efficacy of tenofovir-based rectal microbicides in humans. Future studies will leverage the 
results from this work and the BLT model to perform dose-ranging tenofovir studies, evaluate 
rectal-specific gel formulations containing tenofovir and evaluate other topical rectal microbicide 
agents for efficacy. 
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MATERIALS AND METHODS 
 
Preparation of BLT mice and characterization of human reconstitution.  
 
BLT mice were prepared essentially as previously described [178-185, 187, 200]. Briefly, 
thy/liv implanted [250] and preconditioned NOD/SCID-gamma chain null (NSG) mice (Jackson 
Laboratories, Bar Harbor, ME) were transplanted with autologous human fetal liver CD34
+
 cells 
(Advanced Bioscience Resources, Alameda, CA) and monitored for human reconstitution in 
peripheral blood by flow cytometry [183, 185, 187]. Mice were maintained at the University of 
North Carolina at Chapel Hill Division of Laboratory Animal Medicine in accordance with 
protocols approved by the Institutional Animal Care and Use Committee.  
 
Topical application of tenofovir and rectal exposure of BLT mice to HIV-1.  
 
Stocks of HIV-1JRCSF [251] and HIV-1THRO [243] were prepared and titered as we have 
previously described [181, 252]. Mice were exposed rectally using 0.6 g p24 of HIV-1JRCSF 
(4x10
6
 TCIU, tissue culture infectious units) and 0.7 g p24 of HIV-1THRO (5x10
6
 TCIU). 
Topical tenofovir consisted of 1% tenofovir (PMPA; 9-(2-phosphonyl-methoxypropyly)-
adenine) in PBS. The vehicle (placebo) control was PBS. 
The exposure timeline (Figure 1) consisted of rectal application of vehicle or of 1% 
tenofovir less than 30 minutes prior to rectal application of virus. Rectal exposures with HIV-
1JRCSF and HIV-1THRO were performed essentially as previously described [184, 187] except that 
all the mucosal exposures were carried out atraumatically and without simulated rectal 
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intercourse [253]. All rectal applications of vehicle or inhibitor as well as virus were performed 
while mice were anesthetized [184, 187]. After viral exposure, mice were returned to their 
housing to recover and were then monitored longitudinally for evidence of HIV-1 infection as 
indicated below. 
 
Analysis of HIV-1 infection of BLT mice.  
 
Infection of BLT mice with HIV-1 was monitored at the indicated time intervals in 
peripheral blood by determining plasma levels of viral RNA using real time PCR (limit of 
detection 750 copies/ml) [179, 180] and by monitoring CD4
+
 T cell percentages by flow 
cytometry [183, 184]. At necropsy, tissues were harvested and mononuclear cells isolated as 
previously described [178, 180, 183, 185, 187]. Mononuclear cells were washed, enumerated and 
tested using real time PCR for the presence of HIV-1 DNA (limit of detection 10 copies) [180, 
181, 183, 184]. 
Sequence analysis was performed on plasma RNA samples in the sole case of 
breakthrough infection of a tenofovir-treated, HIV-1JRCSF-exposed BLT mouse. The entire 
reverse transcriptase gene from plasma HIV-1 RNA amplification products was sequenced. No 
resistance mutations in reverse transcriptase were present [103, 115, 116, 254]. 
 
Statistics.  
 
 All statistical analyses (alpha level: 0.05) were performed using Prism v. 5 (Graph Pad 
Software). Kaplan-Meier plots indicate the percentage of animals that are HIV-1 positive in the 
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peripheral blood at each time point analyzed. Power analysis calculation for experimental group 
sample sizes were determined as previously described [255, 256]. Briefly, we assumed 50 and 
65% variance in transmission between our experimental groups for HIV-1JRCSF and HIV-1THRO, 
respectively. In the case of each viral isolate, the chosen sample sizes were determined to have 
90% power to detect statistically significant differences via log rank test analysis in the treatment 
arm versus the vehicle arm. 
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Table 1. BLT mice used to test the efficacy of topical tenofovir to prevent rectal HIV-1JRCSF transmission.*  
       
 Mouse 
% human CD45
+
 
in PB at exposure 
% hCD45
+
 hCD3
+
          
hCD4
+
 in PB at exposure 
Tissue Cell associated viral 
DNA^ 
HIV 
Status 
T
o
p
ic
a
l 
T
e
n
o
fo
v
ir
 
J01 78 87 B, S, O, LN Neg 
J02 69 86 B, S, O, LN, Neg 
J03 67 79 B, S, O, LN Neg 
J04 39 83 B, S, O, LN Neg 
J05 78 67 B, S, O, LN Pos 
J06 54 84 B, O, LN Neg 
J07 69 71 B, S, LN Neg 
J08 73 68 BM, S, O, LN Neg 
J09 86 69 ND Neg 
J10 65 88 BM, S, O, LN Neg 
J11 79 86 B, S, O Neg 
J12 80 86 BM, S, O, LN Neg 
Mean  
(+/- SD) 
70%  
(+/-13) 
80%  
(+/-8) 
 
 
V
e
h
ic
le
 
J13 73 88 B, S, O, LN Pos 
J14 52 79 ND Neg 
J15 32 85 ND Neg 
J16 84 73 B, S, O, LN,  Pos 
J17 68 86 ND Pos 
J18 56 85 ND Neg 
J19 31 79 B, S Pos 
J20 83 72 B, O, S,  Neg 
J21 61 71 S, O, LN, Pos 
J22 71 83 ND Neg 
J23 79 88 B, S, O, LN Neg 
J24 62 84 B, S, O, LN Neg 
J25 72 84 ND Neg 
J26 60 80 S, O, LN Pos 
J27 75 82 B, S, O, LN Neg 
J28 76 88 B, S, O, LN Pos 
J29 77 87 ND Pos 
Mean  
(+/- SD) 
65%  
(+/-16) 
82%  
(+/-6)  
*The data shown in the table includes analyses performed on both infected and uninfected mice with the text in bold 
used to highlight that HIV-1 was found in the indicated tissues. 
^Abbreviations: B – bone marrow; LN –lymph nodes; ND - not done; Neg – negative; O – thymic organoid; PB – 
peripheral blood;; Pos – positive; and S – spleen. 
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Table 2. BLT mice used to test the efficacy of topical tenofovir to prevent rectal HIV-1THRO transmission.* 
       
 Mouse 
% human CD45+ 
in PB at exposure 
% hCD45+ hCD3+          
hCD4+ in PB at exposure 
Tissue Cell associated viral 
DNA^ 
HIV 
Status 
T
o
p
ic
a
l 
T
e
n
o
fo
v
ir
 T01 56 83 B, S, O, LN Neg 
T02 81 81 B, S, O, LN Neg 
T03 82 77 B, S, O, LN Neg 
T04 87 82 B, S, O, LN Neg 
T05 24 80 B, S, O, LN Neg 
T06 29 80 B, S, O, LN  Neg 
Mean  
(+/- SD) 
60%  
(+/-28) 
81%  
(+/-2) 
   
V
e
h
ic
le
 
T07 61 82 B, S, O, Pos 
T08 85 81 B, S, O, LN Neg 
T09 70 76 B, S, O Pos 
T10 86 78 B, S, O Pos 
T11 42 83 B, S, O Pos 
T12 56 77 ND Neg 
T13 83 75 B, S, O,LN Neg 
T14 73 78 ND Pos 
Mean  
(+/- SD) 
70%  
(+/-16) 
79%  
(+/-3) 
 
*The data shown in the table includes analyses performed on both infected and uninfected mice with the 
text in bold used to highlight that HIV-1 was found in the indicated tissues. 
 ^Abbreviations: B – bone marrow; LN –lymph nodes; ND - not done; Neg – negative; O – thymic 
organoid; PB – peripheral blood;; Pos – positive; and S – spleen. 
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Figure 1: Experimental design and timeline 
 
 BLT mice were utilized to determine the efficacy of topically applied tenofovir to prevent 
rectal HIV-1 transmission. Rectal HIV-1 exposures were performed within 30 minutes following 
rectal application of 1% tenofovir. Plasma viral load and real time PCR amplification of tissue 
associated viral DNA were used as HIV-1 detection strategies to determine whether peripheral 
blood samples collected at the indicated times and tissues collected at harvest contained HIV-1. 
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Figure 2: Analysis of peripheral blood and tissues for the presence of HIV-1JRCSF after 
rectal exposure in the presence or absence of topical tenofovir 
 
 (A-B) Longitudinal analyses of peripheral blood plasma viral RNA (A) and the 
percentage of peripheral blood CD3
+
 T cells also expressing CD4 (B) are presented for vehicle 
(left) and topical tenofovir (right) -treated BLT mice exposed rectally to HIV-1JRCSF. (C) Real-
time PCR analysis of tissues for presence or absence of HIV-1 DNA. Thin dashed lines represent 
the limit of detection for the respective assays. Error bars indicate standard error of the mean. 
Open symbols are used to depict data from HIV negative mice and closed symbols are used to 
depict data from HIV positive mice. 
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Figure 3: Topical tenofovir prevents rectal HIV-1JRCSF transmission in BLT mice. 
 
 Kaplan-Meier plot indicates the time to detectionof viral RNA or DNA following rectal 
HIV-1JRCSF exposure in BLT mice pretreated with either vehicle or topical tenofovir. Log-rank 
(Mantel Cox) analysis reveals a statistically significant difference in rectal HIV-1JRCSF 
transmission between the vehicle and topical tenofovir arms. 
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Figure 4: Analysis of peripheral blood and tissues for the presence of HIV-1THRO after 
rectal exposure in the presence or absence of topical tenofovir 
 
 (A-B) Longitudinal analyses of peripheral blood plasma viral RNA (A) and the 
percentage of peripheral blood CD3
+
 T cells also expressing CD4 (B) are presented for vehicle 
(left) and topical tenofovir (right) -treated BLT mice exposed rectally to HIV-1THRO. (C) Real-
time PCR analysis of tissues for presence or absence of HIV-1 DNA. Thin dashed lines represent 
the limit of detection for the respective assays. Error bars indicate standard error of the mean. 
Open symbols are used to depict data from HIV negative mice and closed symbols are used to 
depict data from HIV positive mice.  
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Figure 5: Topical tenofovir prevents rectal transmission of HIV-1THRO, a T/F virus, in BLT 
mice 
 
 Kaplan-Meier plot indicates the time to detection of viral RNA or DNA following rectal 
HIV-1THRO exposure in BLT mice pretreated with either vehicle or topical tenofovir. Log-rank 
(Mantel Cox) analysis reveals a statistically significant difference in rectal HIV-1THRO 
transmission between the vehicle and topical tenofovir arms. 
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CHAPTER III.  INEFFICIENT VAGINAL TRANSMISSION OF TENOFOVIR 
RESISTANT HIV-1 
2 
 
 
 
AUTHOR SUMMARY 
 
 Transmission of drug resistant HIV has been postulated to be a threat to current first line 
antiretroviral therapy (ART) regimes and the efficacy of several antiretroviral based pre-
exposure prophylaxis (PrEP) strategies being tested. Here we evaluated the effect of the common 
tenofovir (TFV) resistance mutation, K65R on vaginal HIV transmission. Our results 
demonstrate that despite no overt loss of overall replication competence in vivo, this mutation 
results in significantly reduced mucosal transmission. When transmitted the mutant virus 
eventually reverts to wild type in the absence of drug therapy. 
 
  
INTRODUCTION 
 
 In absence of a cure or vaccine, and despite valuable efforts toward better HIV education 
including safe sex practices, the HIV epidemic continues to grow at a faster pace than the current 
availability of antiretroviral therapy (ART). For every two people who begin ART, five are 
newly infected [2]. Of the people infected, only 47% have access to ART in low and middle 
income countries [3].  There is a great need to prevent transmission of HIV. To address this need,  
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extensive efforts are being made to develop and implement effective pre-exposure prophylaxis 
(PrEP) approaches. So far, the greatest progress has been made using antiretroviral drug based 
treatment as prevention and PrEP [14, 93]. When the patient has a positive diagnosis and access 
to ART, then early treatment is highly effective at preventing transmission of HIV to uninfected 
partners [14].  Unfortunately, a significant number of HIV+ individuals do not know their 
infection status, especially during acute infection when transmission potential is highest [248]. 
Most current PrEP clinical trials are investigating the use of antiretroviral drugs either singularly 
or as a two drug combination for systemic or topical use [21, 22, 24, 26, 93]. This raises an 
important concern with the dual use of antiretroviral drugs for both treatment and prevention: the 
consequences of the development and transmission of drug resistant HIV. 
HIV-1 develops resistance to virtually all drugs currently available for treatment [103, 
104]. For this reason, current ART therapies consist of a cocktail of multiple drugs with different 
classes of action to prevent or at least postpone the development of drug resistant HIV within the 
patient’s lifespan. Drug-resistant viruses can be transmitted [121-124] .  During new infections 
certain mutations like M184V are rarely detected by routine genotyping but significantly higher 
proportions can be detected using more specific methodology [121-123]. The inherent ability of 
replicating HIV to revert to a drug sensitive genotype in the absence of drug pressure makes it 
difficult to study in patients especially if: (1) the time/duration/route of infection are unknown, 
(2) there is no way to prove ART naïve status, and (3) the HIV sequence in the infecting partner 
is unknown.  Despite these difficulties, genotypic analysis of ART naïve patients has provided 
evidence that drug resistant HIV-1 is being transmitted and can result in treatment failure [125-
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131]. Given that animal studies are the best option to overcome the inherent limitations of human 
studies [257], we utilized humanized mice to investigate in vivo transmission of a drug resistant 
HIV-1. 
 Currently, transmitted drug resistant HIV is very rare, but the novel use of antiretroviral 
drugs for prevention as well as treatment has generated some concerns. Since tenofovir is the 
furthest along for development as a topical microbicide and is one of the two drugs that make up 
the only approved systemic PrEP Truvada, it is logical to look at tenofovir resistant HIV. Given 
that animal studies are the best option to overcome the inherent limitations of human studies 
[257], we utilized humanized mice to investigate in vivo transmission of a drug resistant HIV-1. 
 Tenofovir (TFV) is the drug most commonly used in clinical trials evaluating systemic 
and topical PrEP. Tenofovir disoproxil fumarate, the oral formulation of TFV, is also part of 
every DHHS recommended first line therapy [258]. For this reason, we chose to study 
transmission of a tenofovir resistant HIV. The mutation of the lysine at amino acid position 65 in 
HIV reverse transcriptase to an arginine (K65R) confers resistance to tenofovir as well as other 
NRTIs. For this reason K65R is on both the WHO and IAS surveillance lists for HIV genotyping 
[103, 104]. Analysis of crystal structures suggests that the lysine at position 65 normally interacts 
with the incoming dNTP to form a salt bridge between the gamma phosphate of the dNTP and 
the epsilon amino group of the lysine [116, 259]. This interaction is lost when arginine is 
substituted for lysine and therefore the interactions between enzyme and triphospahte bearing 
molecules (like NRTIs and dNTP) is reduced [116]. The end result is a reduced replication 
capacity (loss of dNTP interaction) but a reduced susceptibility to tenofovir (loss of NRTI 
interactions) [116]. 
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 There is clinical evidence that HIV containing the K65R mutation can be transmitted 
after mucosal exposure albeit at lower frequency than other mutations like M184V [121, 122, 
125, 131]. To evaluate the role of this single amino acid mutation on mucosal HIV transmission, 
we introduced the K65R mutation (AAA to AGA)  into a  proviral clone of HIV-1JR-CSF [251]. In 
addition, to differentiate the mutant virus from the parental clone after reversion, a second, silent 
mutation (TAT to TAC, Tyrosine) was included to act as a molecular marker. 
 
RESULTS 
 
The K65R mutation in viral reverse transcriptase increases resistance to TFV 
To confirm a decrease in the susceptibility of the mutant virus to TFV, we determined the 
in vitro IC50 for wild type HIVJR-CSF and the isogenic mutant, HIVJR-CSF K65R. The K65R mutation 
conferred a 4.7 fold increase in the in vitro IC50 for TFV, which is comparable to the 2 to 4 fold 
range reduction in susceptibility reported [115, 260] (Figure 6).  
 
HIVJRCSF K65R replicates in vivo but fitness defects result in reversion to wild type 
Previous in vitro studies have shown that the K65R mutation reduces the function of viral 
reverse transcriptase [115, 119].  It is unknown to what extent this defect affects viral replication 
in vivo. To test the in vivo replication capacity of HIVJR-CSF K65R, humanized mice [261, 262] 
were inoculated via IP injection 3x10
4
 TCIU and viral load in plasma was monitored over time 
[180]. Longitudinal analysis of plasma viral load showed no difference in the in vivo replication 
of the K65R and wild type strains (Figure 7) demonstrating the in vivo fitness of the mutant 
virus. Sequence analysis of plasma virus RNA from HIV-1JR-CSF K65R infected mice confirmed 
the presence of the K65R mutation 2 weeks post infection. However, subsequent time points 
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showed a population of wild type virus. Sequence analysis indicated that reversion of the K65R 
mutation was always to the original sequence. It should be noted that the molecular marker, 
present only in the mutant virus, served to exclude the possibility of contamination with wild 
type virus. 
 Having demonstrated the replication capacity of the K65R mutant virus in vivo, we next 
evaluated its capacity to transmit mucosally. For this purpose, we utilized BLT humanized mice 
[180]. The female reproductive tract of BLT mice is reconstituted with all the cells relevant for 
HIV transmission including human T cells, monocyte/macrophages and dendritic cells [180, 
204]. BLT mice were vaginally exposed once to equal infectious doses of wild type HIV-1JR-CSF 
or the isogenic K65R mutant virus (3.5X10
5
 TCIU).  Three independent exposures (n=4) were 
performed on three different dates.  The results of these vaginal exposures showed a dramatic 
decrease in the transmission efficiency of the K65R mutant virus (Figure 8). Specifically, 
whereas all the mice exposed to the wild type virus were infected (4/4) only 25% of the mice 
exposed to the mutant virus were infected (3/12). This difference in vaginal HIV transmission 
was highly statistically significant by log rank analysis (p=0.011, Mantel Cox). These results 
demonstrate that the K65R mutant is vaginally transmitted at a greatly reduced rate compared to 
the wild type virus.  Interestingly, these results seem at odds with those recently published by 
Cong et al [257] using SIV.  However, these could due to the facts that a different mutation was 
used and that additional fitness compensatory mutations were introduced into the provirus used 
by Cong et al [257].  
To determine if the transmitted virus contained the K65R mutation, plasma viral RNA 
was sequenced at different times after exposure. Four weeks post exposure we noted the 
presence of only mutant virus in one mouse (M1), the presence of only wild type (reverted) virus 
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in a second mouse (M2), and the presence of both mutant virus and wild type (reverted) virus 
populations in a third mouse (M3). Longitudinal analysis of the virus found in the plasma of one 
of the infected mice (M3) showed the presence of both mutant and wild type viruses at weeks 4 
and 6 post infection and the presence of wild type virus at all subsequent time points (Table 1). 
Cervicovaginal lavage (CVL) from this mouse also showed the presence of both wild type and 
mutant virus 4 weeks post infection. Subsequently only the wild type virus was found in the 
CVL (Table 1). Analysis of the virus present in the different tissues from two of the infected 
mice generally reflected what was observed in the periphery. However, in one mouse the mutant 
virus was found in the plasma but all tissues analyzed contained both the wild type and mutant 
viruses. Interestingly, analysis of the virus present in tissues 14 weeks post infection showed the 
wild type virus in all tissues except thymus where both drug resistant and wild type virus were 
found (Table 1).  These results are consistent with the hypothesis of Weinberg et al suggesting 
that transmitted viruses that contain reversible mutations become archived in lymphocyte 
reservoirs [123].   
 
DISCUSSION 
 
 
 The topical or systemic use of antiretroviral drugs for the purpose of preventing HIV 
acquisition has the potential to curtail the spread of AIDS and some PrEP strategies have shown 
great promise [14, 22, 26, 263, 264]. The fact that tenofovir is a successful first line drug for the 
treatment of HIV infection has made this compound the drug of choice for most prevention trials 
[265]. However, this dual use approach is not without risk as there is significant potential to 
expand the pool of drug resistance in communities utilizing PrEP [15, 264]. Here we test K65R 
mutated HIV-1 in humanized mice and found that, as in humans, the HIV carrying the K65R 
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mutation is (1) replication competent (Figure 7); (2) is present in cervicovaginal secretions 
(Table 3); and (3) reverts to wild type in the absence of drug selection although the mutant virus 
remains detectable (Table 3). The reversion to wild type in our humanized mouse model 
replicates what is predicted to occur in human patients [266]. It is important to note, that in the 
absence fo drug pressure, the K65R mutation reverts to a wildtype/drug sensitive genotype both 
in the peripheral blood and female reproductive tract. This suggests that despite being initially 
infected with a tenofovir resistant HIV, an individual who is not taking ART is more likely to 
transmit a drug sensitive form of HIV. 
 Patients initially infected with a viron contaiing the K65R mutation may form latently 
infected cells with this tenofovir resistant version of HIV before the virues reversts to a 
tenofovir-sensitive genotype. Then, upon initiation of tenofovir based  ART, there is a greater 
chance of re-emergence of the original drug resistant form. Fourtunatly, the K65R mutation is 
specific to NRTI RT inhibitors so a virus containing only a K65R mutation will remain sensitive 
to protiease, integrage, and NNRTIs. 
 Finally, we tested the transmission efficiency of the  K65R mutant HIV and found that it 
could transmit, albeit at a significantly lower efficiency than wild type HIV (Figure 8). Several 
clinical trials have been done to evaluate the efficacy of tenofovir or tenofovir disoproxil 
fumarate to prevent HIV transmission. One concern has been that a virus containing a tenofovir 
resistance mutation such as K65R will be able to transmit despite the use of a TFV/TDF PrEP. 
Given our results, it seams the benefit of drug resistance is overshadowed by a severe defect in 
transmission. It is possible that the protective efficacy of a TFV/TDF PrEP is sufficient to 
prevent transmission of K65R containing HIV. Overall, our results demonstrate that if this 
tenofovir resistant virus is present in the transmitting partner, there is the potential for the mutant 
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virus to be transmitted to the uninfected partner with lower efficiency compared to wild type 
HIV-1. 
 
MATERIALS AND METHODS 
 
 
Preparation of BLT mice and characterization of human reconstitution.  
BLT mice were prepared essentially as previously described [178-185, 187, 200]. Briefly, 
thy/liv implanted [250] and preconditioned NOD/SCID-gamma chain null (NSG) mice (Jackson 
Laboratories, Bar Harbor, ME) were transplanted with autologous human fetal liver CD34
+
 cells 
(Advanced Bioscience Resources, Alameda, CA) and monitored for human reconstitution in 
peripheral blood by flow cytometry [183, 185, 187]. Mice were maintained at the University of 
North Carolina at Chapel Hill Division of Laboratory Animal Medicine in accordance with 
protocols approved by the Institutional Animal Care and Use Committee.  
 
IP andVaginal exposure of BLT mice to HIV-1.  
Stocks of HIV-1JRCSF [251] and HIV-1JRCSF(K65R) were prepared and titered as we have 
previously described [181, 252]. Mice were exposed intraperitoneally (IP) using 3x10^4 TCIU of 
HIV-1JRCSF  or HIV-1JRCSF(K65R). Mice were exposed vaginally using 3.5x10^5 TCIU of HIV-
1JRCSF  or HIV-1JRCSF(K65R) . After viral exposure, mice were returned to their housing to recover 
and were then monitored longitudinally for evidence of HIV-1 infection as indicated below. 
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Analysis of HIV-1 infection of BLT mice.  
Infection of BLT mice with HIV-1 was monitored at the indicated time intervals in 
peripheral blood by determining plasma levels of viral RNA using real time PCR (limit of 
detection 750 copies/ml) [179, 180] and by monitoring CD4
+
 T cell percentages by flow 
cytometry [183, 184]. At necropsy, tissues were harvested and mononuclear cells isolated as 
previously described [178, 180, 183, 185, 187]. Mononuclear cells were washed, enumerated and 
tested using real time PCR for the presence of HIV-1 DNA (limit of detection 10 copies) [180, 
181, 183, 184]. 
Sequence analysis was performed on RNA and DNA samples in the cases of successful 
transmission of HIV-1JRCSF(K65R) exposed BLT mouse. The entire reverse transcriptase gene from 
plasma HIV-1 RNA amplification products was sequenced. Resistance mutations in reverse 
transcriptase were present or absent as described in table [103, 115, 116, 254]. 
 
Statistics.  
 All statistical analyses (alpha level: 0.05) were performed using Prism v. 5 (Graph Pad 
Software). Kaplan-Meier plots indicate the percentage of animals that are HIV-1 positive in the 
peripheral blood at each time point analyzed. Power analysis calculation for experimental group 
sample sizes were determined as previously described [255, 256]. Briefly, we assumed 50 and 
65% variance in transmission between our experimental groups for HIV-1JRCSF and HIV-
1JRCSF(K65R), respectively. In the case of each viral isolate, the chosen sample sizes were 
determined to have 90% power to detect statistically significant differences via log rank test 
analysis in the treatment arm versus the vehicle arm. 
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Figure 6. Introduction of K65R mutation into HIVJR-CSF results in a 4.7 fold increase of in 
vitro IC50  using a luciferase based assay in TZM-bl indicator cells. 
 
 Serial dilutions of tenofovir were applied to indicator cells in triplicate and allowed to 
incubate for 30 mins before an equal number of tissue culture infectious units (TCIU) of either 
wild type or mutant virus was applied to all wells. Two days later, the media is removed, ONE-
GLO reagent (Promega) was added and the amount of luciferase activity was measured. Each 
curve was normalized to wells infected with that specific virus (wild type or K65R virus) in the 
absence of drug.  RLU= relative light units. 
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Figure 7. In vivo replication of HIVJR-CSF and HIVJR-CSF K65R after IP injection into 
humanized mice shows no overt difference in replication capacity 
 
 Humanized NOD/SCID/gamma
-/-
 mice [261, 262] were infected with equal amounts of 
either HIV-1JR-CSF or HIV-1JR-CSF K65R (3x10
4
 TCIU) by IP injection.  The course of infection was 
monitored by determining plasma viral loads. 
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Figure 8. The K65R mutation reduces vaginal transmission efficiency of HIV-1 by 75% 
 
 Humanized BLT mice were prepared and validated as previously described [180, 185, 
204].  Mice were exposed vaginally to a single dose of HIV-1JR-CSF or HIV-1JR-CSF K65R (3.5x10
5
 
TCIU).  Infection was monitored as a function of viral load in plasma. Kaplan-Meyer plot 
represents the percentage of HIV negative mice as a function of the number of weeks post-
exposure until the first peripheral blood HIV-1 detection.  Of the mice exposed to wild type 
HIVJRCSF, 4 of 4 mice had detectable viral RNA by week 2 post exposure. Of the mice exposed 
to the K65R mutant HIV, 3 of 12 (25%) mice viral load was readily detectable 2 weeks post 
exposure. The remaining 9 of12 mice (75%) mice exposed to the K65R mutant no viral load was 
detected at any time point analyzed and no viral DNA was found in tissues at harvest confirming 
lack of transmission. 
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TABLE 3. Sequence analysis demonstrates reversion of the K65R mutation over time in 
peripheral blood, cervicovaginal lavage and tissues of infected BLT mice*.  
Vaginally 
infected by 
HIVJR-CSFK65R 
Week post 
exposure 
Analysis of Viral Sequence from Bulk PCR Products at Position 65   
Peripheral 
blood 
Vaginal 
lavage 
FRT 
Lymph 
node 
Organoid 
implant 
Lung 
M1 4 R only n/a 
 
n/a K and R K and R K and R 
 
M2 4 K only n/a 
 
n/a K only  K only K only 
 
M3 4 K and R K and R     
 6 K and R K only     
 9 K only K only     
 13 K only K only     
 14 K only K only K only K only K and R K only 
*
Bone marrow/liver/thymus mice were exposed once intravaginally once to mutant virus.  
Infection was monitored in plasma by determining viral load.  Two mice were harvested four 
weeks post infection (M1 and M2) and one was harvested 14 weeks post exposure (M3).  
Peripheral blood and vaginal lavage samples from this mouse were collected longitudinally.  Only  
FRT, female reproductive tract. K, lysine.  R, arginine.  PCR primer sets used to amplify RT: 
outer/first reaction: 5’-GCTCTATTAGATACAGGAGC-3’, 5’-
CCTAATGCATATTGTGAGTCTG-3’, inner/second reaction :5’-
GTAGGACCTACACCTGTCAAC-3’, 5’-CCTGCAAAGCTAGGTGAATTGC-3’.Amplification 
products were sequenced in bulk. 
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CHAPTER IV. EVALUATION OF AN ENTRY INHIBITOR FOR USE AS PREP
3 
 
 
 
AUTHOR SUMMARY 
 
 
 Antiretroviral drugs from the entry inhibitor class have the potential to be highly effective 
at preventing transmission of HIV when used as a pre-exposure prophylaxis. Unlike tenofovir, 
entry inhibitors are not part of first line therapies which would reduce the likelihood of PrEP 
resulting in resistance to ART. Alternatively, combining drugs from multiple classes could 
increase the efficacy of PrEP and offer a wider spectrum of protection. For these reasons, we 
chose to evaluate the entry inhibitor Maraviroc for its potential to prevent HIV transmission. 
Utilizing BLT humanized mice, Maraviroc administered once a day orally prevented vaginal 
HIV transmission. One percent Maraviroc applied vaginally completely prevented vaginal HIV 
transmission. The same solution applied rectally also resulted in complete protection from rectal 
HIV transmission. In summary, these studies support the use of the entry inhibitor Maraviroc as 
an effective candidate drug for both oral and topical PrEP. 
  
 
INTRODUCTION 
  
 As described in the previous chapters, the use of multiple antiretroviral drugs for PrEP 
stratagies will help prevent the in vivo selection and the transmission of drug resistant HIV. In 
addition, utilization of multiple antiretroviral drugs has the potential to combine drugs with  
___________________________ 
3 
The following work is unpublished data. 
 
Author contributions are as follows:  conceived and designed the experiments, MC, MS 
performed the experiments, MC ; analyzed the data, MC; predicted authors for the paper, MC, 
IM, VG 
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complementary PK/PD profiles, formulation possibilities, and could have an increased protective 
effect by targeting multiple steps of the viral replication cycle. Before developing a multiple drug 
combination for topical PrEP, it is important to establish that the individual drugs each contribute 
to protection. In addition to topical tenofovir, maraviroc has been recently suggested as a 
candidate for topical PrEP [267]. 
 Maraviroc is an antiretroviral drug that prevents HIV from binding to the CCR5 receptor. 
Nearly all new infections are the result of R5-tropic HIV transmission [243, 244]. When used for 
treatment, Maraviroc has the potential for inducing outgrowth of  X4-tropic HIV, a viral tropism 
associated with a more pathogenic infection [268-271]. While studies have shown that treatment 
with Maraviroc does lead to outgrowth of X4-tropic or dual-tropic HIV, there are conflicting 
reports over whether these infections result in increased CD4 decline [268, 269, 272, 273]. In 
addition, patients who discontinue Maraviroc often see a reappearance of R5-tropic virus as the 
dominant viral population. While Maraviroc has been approved for ART, it is not a first line 
therapy drug. In theory, a person using Maraviroc as PrEP could experiences a breakthrough 
infection and the virus may develop resistance to Maraviroc but will maintain sensitivity to first 
line therapy drugs.  
 Pre-clinical trials have found Maraviroc to be protective in humanized mouse models. In 
a 2010 article, RAGhu mice were given Maraviroc once a day by oral gavage for seven days. On 
the fourth day, mice were vaginally exposed to HIVBAL-1. Mice receiving Maraviroc had100% 
protection compared to the control mice. In a 2011 article, RAG-hu mice received a single 
treatment of a 5mM Maraviroc gel applied vaginally and an hour later were vaginally exposed to 
HIVBAL-1. Mice that received the Maraviroc gel were completely protected from vaginal HIV 
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transmission while those that received the placebo gel all became infected. These studies support 
the use of Maraviroc to prevent vaginal HIV transmission whether it is given orally or topically.  
 In macaque models, a 3.3% MVC (by wt) gel was able tocompletey prevent vaginal 
transmsssion of SIV [274]. In this study, a single application of 3.3% MVC gel resulted in peak 
vaginal fluid drug levels at .5-2hrs after application (10
4
 to 10
7
 ng/mL) and drug was detectable 
for up to 72 hours [274]. On the other hand, a different study found no protection from rectal 
exposure when maraviroc was administered orally even though high levels of drug were detected 
in rectal tissue (1.4 ug MVC/g tissue) [275].  
 Building on these studies, we decided to evaluate Maraviroc as a oral or topical PrEP to 
prevent vaginal or rectal transmission of HIV in the BLT humanized mouse model.  We utilized 
the CCR5-tropic, transmitted founder virus HIVTHRO. Transmitted founder viruses represent the 
most biologically relevant, molecular clones of HIV available for PrEP studies.  
 My results demonstrated protection against vaginal transmission when MVC was given 
as a daily oral dose. One percent Maraviroc applied topically resulted in complete protection of 
HIV transmission when applied at the site of exposure. These studies support the use of this 
entry inhibitor for dual compartment use in either oral or topical formulations. 
  
RESULTS 
 
Daily oral Maraviroc prevents vaginal transmission of HIV 
 To test the ability of Maraviroc taken orally to prevent HIV transmission, BLT mice 
(n=4) were administeed Maraviroc (62 mg/kg body weight) via oral gavage once a day for seven 
days. On the third day, the mice were vaginally exposed to 3.5x10
5
 TCIU HIVTHRO. Only 25% (1 
out of 4) of the mice receiving Maraviroc became infected with HIV resulting in a significant 
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level of protection. All of the mice in the control arm became infected with HIV (n=5). (Figure 
10).  
 
Single pre-exposure application of 1% Maraviroc prevents vaginal transmission of HIV 
 To test the ability of Maraviroc applied topically to prevent vaginal HIVTHRO 
transmission, BLT mice (n=4) were administered 1% MVC (≈19mM) vaginally once within 30 
minutes prior to HIV exposure. There was complete protection with statistical significance 
(Figure 11). This provides supporting evidence for development of an efficient Maraviroc based 
topical microbicide to prevent vaginal HIV transmission. 
 
Single pre-exposure application of 1% Maraviroc prevents rectal transmission of HIV 
 To test the ability of Maraviroc applied topically to prevent rectal HIVTHRO transmission, 
BLT mice were administered a single dose of 1% MVC topically within 30 minutes prior to HIV 
exposure. Mice were given MVC rectally and were exposed rectally. There was complete 
protection with statistical significance (Figure 13). This provides supporting evidence for 
development of an efficient Maraviroc based topical microbicide for rectal application. 
 
 
DISCUSSION 
 
 There is great support and building evidence that antiretroviral drugs can effectively 
prevent HIV transmission [18, 23, 180, 184, 265, 276, 277]. To date, the greatest progress has 
been made with Tenofovir containing strategies. The dual use of Tenofovir for prevention and as 
first line therapy has raised concerns including de novo and transmitted tenofovir resistance. 
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These concerns can be addressed by utilization of multidrug PrEP and/or use of an antiretroviral 
drug not commonly used for first line therapy. Antiretroviral drugs from the entry inhibitor class 
are not usually prescribed for first or second line therapy thereby making them excellent 
candidates for PrEP studies.  
 For my studies, the entry inhibitor Maraviroc was evaluated as for PrEP when 
administered orally or topically. Maraviroc is a negative allosteric modulator of the CCR5 
receptor which results in an inability to bind the HIV gp120 protein [278]. Despite being very 
potent and having a good safety profile, Maraviroc is not a first line therapy drug. In terms of 
HIV transmission, the virus transmitted through sexual encounters is almost exclusively CCR5 
tropic with some evidence of occasional dual tropic virus transmission. Therefore, Maraviroc is 
an excellent candidate drug for HIV PrEP prevention strategies. 
 Previously published work in the RAG-hu humanized mouse model has shown 
Maraviroc to be protective against vaginal HIV transmission when administered orally or 
topically [277, 279]. In addition, a recently published study using topical Maraviroc in a 3% by 
wt gel found complete protection in macaque model when used vaginally [274]. Following these 
studies, it was reported that Maraviroc administered orally had no protective effect in a non-
human primate model of rectal transmission despite detectable levels of drug in rectal tissue 
[275]. My results agree with the previous humanized mouse studies concerning vaginal 
transmission and, in addition, demonstrates protection from rectal transmission if Maraviroc is 
used topically.  
 Maraviroc is one of the few anti-HIV drugs that targets a host protein instead of targeting 
to a viral protein.. The human and rhesus CCR5 differs by eight amino acid residues. In 2012, 
Malcolm et. al. measured the EC50 values for Maraviroc when used with human or rhesus 
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PBMCs. The authors reported a 5  fold difference in EC50 when using SHIV-162P3 and a 10 fold 
difference in EC50  when using  SIV-mac251 [280]. These head-to-head in vitro comparisons 
indicate that Maraviroc is less effective at protecting rhesus cells from infection and more 
effective at protecting human cells from infection. Therefore, Maraviroc may not be as effective 
in experimental models where the CCR5 receptor is not human 
 In conclusion, my research supports the use of Maraviroc for effective HIV prevention as 
either an orally administered drug or as a topical application. Orally administered Maraviroc 
provided 75% protection against vaginal HIV transmission. Topically administered Maraviroc 
was able to provide complete protection from either vaginal or rectal exposure making it a good 
candidate for a dual use microbicide. 
 
MATERIAL AND METHODS 
 
Preparation of BLT mice and characterization of human reconstitution.  
BLT mice were prepared essentially as previously described [178-185, 187, 200]. Briefly, 
thy/liv implanted [250] and preconditioned NOD/SCID-gamma chain null (NSG) mice (Jackson 
Laboratories, Bar Harbor, ME) were transplanted with autologous human fetal liver CD34
+
 cells 
(Advanced Bioscience Resources, Alameda, CA) and monitored for human reconstitution in 
peripheral blood by flow cytometry [183, 185, 187]. All BLT mice used herein (n=31) had high 
peripheral blood reconstitution levels of human lymphoid (CD45
+
) cells (74% mean ± 10%, SD) 
and human CD4
+
 T cells (82% mean ± 4%,  SD) (Summarized in Figures 9 and 12 ).Mice were 
maintained at the University of North Carolina at Chapel Hill Division of Laboratory Animal 
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Medicine in accordance with protocols approved by the Institutional Animal Care and Use 
Committee.  
 
MVC solution preparation 
 Maraviroc was purchased from Selleckchem (Cat. S2003, MW 513.67g/mol, >99% 
purity). Maraviroc powder was added to PBS and 1M HCL was added until MVC fully went into 
solution. The pH was then adjusted to neutral using dilute NaOH. Finally, PBS was added to 
solution until reaching a 1% by weight concentration of Maraviroc. The final solution was sterile 
filtered using Nalgen .2µ luer lock filters. The same solution was utilized for both oral gavage 
and topical administration.  
 
Oral dosing of Maraviroc and vaginal exposure of BLT mice to HIV-1 
  
BLT mice in the Maraviroc drug arm received a daily oral gavage of 1.23mg MVC per 
20 gram mouse weight daily for seven days resulting in a total of seven gavages. Two hours after 
the third gavage, the mice were vaginally exposed to 3.5x10
5 
TCIU of HIVTHRO.  
 
Topical application of tenofovir and vaginal or rectal exposure of BLT mice to HIV-1.  
A stock of HIV-1THRO [243] was prepared and titered as we have previously described 
[181, 252]. Mice were exposed rectally using 0.7 g p24 of HIV-1THRO (5x10
6
 TCIU). Topical 
Maraviroc consisted of 1% Maraviroc by weight in PBS. The vehicle (placebo) control was PBS. 
The exposure timeline consisted of rectal application of vehicle or of 1% Maraviroc less 
than 30 minutes prior to rectal application of virus. Rectal exposures with HIV-1THRO were 
performed essentially as previously described [184, 187] except that all the mucosal exposures 
were carried out atraumatically and without simulated rectal intercourse [253]. All rectal 
applications of vehicle or inhibitor as well as virus were performed while mice were anesthetized 
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[184, 187]. After viral exposure, mice were returned to their housing to recover and were then 
monitored longitudinally for evidence of HIV-1 infection as indicated below. 
 
Analysis of HIV-1 infection of BLT mice.  
Infection of BLT mice with HIV-1 was monitored at the indicated time intervals in 
peripheral blood by determining plasma levels of viral RNA using real time PCR (limit of 
detection 750 copies/ml) [179, 180] and by monitoring CD4
+
 T cell percentages by flow 
cytometry [183, 184]. At necropsy, tissues were harvested and mononuclear cells isolated as 
previously described [178, 180, 183, 185, 187]. Mononuclear cells were washed, enumerated and 
tested using real time PCR for the presence of HIV-1 DNA (limit of detection 10 copies) [180, 
181, 183, 184]. 
 
Statistics. 
 All statistical analyses (alpha level: 0.05) were performed using Prism v. 5 (Graph Pad 
Software). Kaplan-Meier plots indicate the percentage of animals that are HIV-1 negative in the 
peripheral blood at each time point analyzed.  
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Figure 9. Characterization of the levels of human cell types present in peripheral blood of 
BLT mice used in vaginal exposure studies 
 
 Prior to vaginal exposure, the peripheral blood of each mouse was analyzed by flow 
cytometry for the presence of human hematopoietic cells (CD45, green bar represents mean), 
human T-cells (CD3, blue bar represents mean), and human CD4+ T cells (CD4, red bar 
represents mean). Mice are grouped by experimental arm: no drug controls (PBS), daily oral 
MVC administration (Oral MVC), and single application of topical 1% MVC (Vag MVC). Data 
points depicted in red represent animals that became infected with HIV. Overall, the mice in all 
experimental arms had comparable in levels of human cells (t-test). 
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Figure 10. Orally administered Maraviroc prevents vaginal transmission of HIV 
 
 Kaplan-Meier plot indicates the time to detection of viral RNA or DNA following 
vaginal HIV-1THRO exposure in BLT mice pretreated with either vehicle or oral Maraviroc. Log-
rank (Mantel Cox) analysis reveals a statistically significant difference in vaginal HIV-1THRO 
transmission between the vehicle and oral Maraviroc arms. 
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Figure 11. A single application of 1% Maraviroc prevents vaginal transmission of HIV 
 
 Kaplan-Meier plot indicates the time to detection of viral RNA or DNA following 
vaginal HIV-1THRO exposure in BLT mice pretreated with either vehicle or topical MVC. Log-
rank (Mantel Cox) analysis reveals a statistically significant difference in vaginal HIV-1THRO 
transmission between the vehicle and topical MVC arms. 
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Figure 12. Characterization of the levels of human cell types present in peripheral blood of 
BLT mice used in rectal exposure studies 
  
 Prior to rectal exposure, the peripheral blood of each mouse was analyzed by flow 
cytometry for the presence of human hematopoietic cells (CD45, green bar represents mean), 
human T-cells (CD3, blue bar represents mean), and human CD4+ T cells (CD4, red bar 
represents mean). Mice are grouped by experimental arm: no drug controls (PBS) or a single 
application of topical 1% MVC (MVC). Data points depicted in red represent animals that 
became infected with HIV. Overall, the mice in all experimental arms were comparable in 
humanization. 
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Figure 13. A single topical application of 1% Maraviroc prevents rectal transmission of 
HIV 
 
 Kaplan-Meier plot indicates the time to detection of viral RNA or DNA conversion 
following rectal HIV-1THRO exposure in BLT mice pretreated with either vehicle or topical 
Maraviroc. Log-rank (Mantel Cox) analysis reveals a statistically significant difference in rectal 
HIV-1THRO transmission between the vehicle and topical Maraviroc arms. 
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CHAPTER V. EFFECT OF MICROBIOTA ON HIV TRANSMISSION
4
 
 
 
 
AUTHOR SUMMARY 
 
 The microbiome/microbiota is the aggregate of microorganisms that resides on the 
surface and within the host’s tissues. Each host species contains a microbiome that is unique to 
the host and has co-evolved with that particular species [281, 282]. Fluctuations in microbiome 
composition can exacerbate or suppress immune responses [282, 283]. Microbiome composition 
can affect transmissibility and pathogenesis of infectious agents and opportunistic pathogens 
[151, 284, 285]. Observational studies have suggested that microbiome composition may affect 
HIV transmission and pathogenesis [145, 154, 157]. For this reason, the following work 
describes the first small animal model available to evaluate HIV transmission and pathogenesis 
in the context of differing microbiota. Humanized mice provide the unique ability to evaluate the 
in vivo function of the human immune system in total absence of microbiota or with a few select 
organisms. To achieve this goal, NSG mice were derived in germ free conditions and used to 
establish a germ free NSG colony. These mice were used to generate humanized with a human 
associated microbiome environment. Preliminary results showed that humanized mice with a 
human microbiome have an increased HIV transmission efficiency than humanized mice with a 
murine microbiome. These mice will provide a powerful tool for evaluating the human immune 
system’s response to the presence or absence of a microbiome. We will also evaluate the 
microbiome effect on viral load and CD4
+
 cell decline. 
_______________________________ 
4
The following is unpublished data 
 
Author contributions are as follows: conceived and designed the experiments, MC VG; 
performed the experiments, MC ; analyzed the data, MC; predicted authors for the paper, MC, 
IM, VG 
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INTRODUCTION  
 
   
Microbiome may affect HIV transmission and pathogenesis 
 Several clinical studies have linked microbial populations with HIV transmission and 
pathogenesis [149, 157, 158, 286-288]. Co infections with STDs such as that cause disruption of 
the epithelia layer, genital herpes, or that cause local inflammation, yeast infection, tend to 
increase the likelihood of acquiring an HIV infection [289, 290]. On the other hand, it is 
predicted that the presence of Lactobacillus species will reduce the transmission of HIV [161, 
291]. Therefore, the treatment of current STDs or the use of probiotics may be a way to actively 
reduce HIV transmission. 
 Microbial populations have also been suspected for affecting HIV pathogenesis. CD4
+
 T-
cell decline is one of the defining characteristics of HIV infection. Chronic T-cell activation and 
death has been linked to microbial translocation in the intestinal tract [157, 287, 292-294]. 
Studies to evaluate the effect of microbial composition on HIV pathogenesis may provide unique 
insights into why some individuals progress to AIDS faster or slower than others [287]. 
Ultimately, HIV infection doesn’t kill a person. The opportunistic infections associated with 
AIDS are the direct reason for death of untreated HIV infected patients [155]. 
 
Small animal model to study effect of microbiota on HIV transmission 
 As previously described, humanized mice are made from genetically immune deficient 
mice strains such as NSG. While some microbiome studies are done using massive antibiotic 
treatments to alter commensal microbiota composition, we wanted to create the perfect “empty 
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vessel” for our microbiome studies only achievable by using germ free animals [295, 296]. A 
germ free animal is specifically an animal completely devoid of all bacteria, all fungi, and the 
vast majority of viral species [297, 298]. These animals are born under sterile conditions and 
must remain housed in sterile isolators to maintain their germ free status [299]. We derived a 
germ-free NSG mouse colony de novo at the National Gnotobiotic Rodent Resource Center at 
University of North Carolina, Chapel Hill. Some germ-free NSG mice were removed from germ-
free housing at the age of weaning and given a human microbiome by oral gavage with human 
feces. These human microbiota mice were the used to generate BLT humanized mice. 
Preliminary results show a higher rate of rectal HIV transmission in humanized mice that 
received human microbiota. 
 
 
RESULTS 
 
Different rates of HIV transmission occur at different animal housing locations 
 Prior to 2010, our mice were housed in the animal facilities of the University of Texas 
Southwestern Medical Center at Dallas, TX. At this facility we saw a constant rectal HIV 
transmission efficiency of 63-69% [184, 203]. None of the previous mice or animal equipment 
was relocated to the University of North Carolina Chapel Hill. Initially, at UNC, mice were 
purchased from Jackson Laboratories and were housed in the upper basement level of the 
Genetic Medicine Building (GMB) in a room that had previously housed animals but was 
emptied for our exclusive use (Room 35, upper basement). At this location, we had inconsistent 
rectal HIV transmission with the average transmission of 75% (62% to 100%) for mice rectally 
exposed to 5x10
6
 TCIU HIVTHRO (n=12). One year later, a brand new, never used before animal 
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housing space became available for our use in the lower basement of GMB (Room 35, lower 
basement). No animals were relocated to the lower basement. Rather new animals were 
purchased from Jackson Laboratories. At this new location, we had a severely reduced rate of 
rectal HIV transmission of 18% (0 to 50%) for mice rectally exposed to 5x10
6
 TCIU HIVTHRO 
(n=22). In response to this severe decrease in rectal transmissions, we wished to return to the 
upper basement housing (Room 35, upper basement) for our experiments but this room had been 
repurposed and was unavailable. As an alternative, we made use of animal housing in another 
room of the upper basement where multiple laboratories housed several strains of mice (Room 
40, upper basement). Room 41 of the upper basement is a shared space with common use 
ventilated hoods for animal manipulations. For rectal exposures, BLT animals were generated in 
the lower basement Room 35 and relocated to the upper basement Room 40 where they were put 
on old bedding and allowed to acclimate to the housing conditions and local microbial 
populations for at least two weeks before exposure. Rectal HIV transmission was consistently 
50% (50% every experiment) for mice rectally exposed to 5x10
6
 TCIU HIVTHRO in Room 40 of 
the GMB upper basement (n=10). All of these results are depicted in Figure 14. Taken together, 
we hypothesized that the greatest factor affecting rectal HIV transmission efficiency was the 
local microbiota present in each housing location. 
 
Humanized mice with human microbiota have optimal rectal HIV transmission 
 All mice in the previous experiments were either supplied directly from Jackson 
Laboratories or bred in our housing from Jackson Laboratory mice. Therefore, we would expect 
the microbiota of our mice to be a mixture of the original microbiota acquired at Jackson 
breeding facility and an addition of some microbiota acquired in our housing.  
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 To evaluate the effect of a human associated microbiome (HuMb) on HIV transmission, 
we inoculated germ free NSG mice via human fecal transplant and had no adverse events. These 
mice were housed in their own room separate from any other animal housing area. These mice 
were then humanized using the BLT protocol and exposed rectally to 5x10
6
 TCIU HIVTHRO. 
HuMb BLT mice had the highest transmission efficiency of all other housing conditions at 83% 
(n=6). These results suggest that HIV transmission in BLT mice is affected by the microbiome 
and that the human microbiome is optimal for HIV transmission in humanized mice. Further 
studies are needed to determine which components of the microbiome are responsible for the 
effect on HIV transmission. 
 
DISCUSSION 
  
 HIV transmission primarily occurs at mucosal sites of sexual exposure. These sites are 
colonized with a community of commensal organisms some of which are opportunistic 
pathogens [300, 301]. Clinical trials evaluating HIV transmission have suggested that the 
composition of microbiota at these mucosal surfaces affects HIV transmission [145, 155, 157]. 
Unfortunately, HIV transmission studies involving humans can be inherently difficult. To 
address this issue, we developed a novel humanized mouse model capable of evaluating the 
effect of microbiota on HIV transmission and pathogenesis. Germ free NSG mice were colonized 
with a human microbiota (HuMb) and then given a human immune system (BLT) to create a 
HuMb BLT experimental model. HuMb BLT mice rectally exposed to HIV resulted in 
transmission of 83% of the mice. This transmission efficiency is higher than any previous BLT 
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mouse regardless of housing conditions. Therefore, we provide evidence showing the dramatic 
effect of microbial populations to affect HIV transmission.  
 HuMB BLT mice were also tested for vaginal and oral transmission of HIV-1. All mice 
exposed to HIV-1JR-CSF vaginally became infected (Figure 15). Mice orally exposed to HIV-
1JRCSF were also susceptible to infection (75% transmission, Figure 15). Further studies will be 
needed to determine the relative transmission efficiencies between HuMB BLT and BLT mice 
with a murine microbiome. 
 Future studies to be done with HuMb BLT mice include 1) determining if specific species 
or genus of organisms can be sufficient to increase HIV transmission in conventionally housed 
BLT mice, 2) determine if alterations in microbiome composition affects HIV pathogenesis, 3) 
determine if cohousing HuMb BLT mice with conventional MMb BLT mice affects transmission 
efficiency, and 4) determine how antibiotic or antifungal treatments affect microbiome 
composition and HIV transmission. In addition, the availability of germ free NSG mice gives us 
the opportunity to perform mono-colonization studies, probiotic studies, or test the efficacy of 
anti-HIV living microbicides under development. 
 
MATERIALS AND METHODS 
 
Derivation of germ free NSG mice 
 
 Germ free NSG mice were derived and housed at the National Gnotobiotic Rodent 
Resource Center at the University of North Carolina, Chapel Hill NC. Conventially housed NSG 
females received hormone injections to induce superovulation. These superovulated females 
were then co-housed with male NSG mice and fertilization was verified by the presence of a 
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sperm plug. NSG embryos were removed under sterile conditions and evaluated ex vivo for 
quality. High quality embryos were transferred under sterile conditions into a germ free, 
surrogate female mouse. The surrogate mother carried the NSG embryos to term and gave birth 
to a litter of germ free NSG pups. Brother sister mating was used to found a colony of germ free 
NSG mice. 
 
Colonization of germ free mice with human microbiota 
 
 A human fecal sample was obtained from a healthy adult donor and homogenized with 
PBS before freezing 97 aliquots in liquid nitrogen storage. An aliquot was sent to Charles River 
for PCR analysis to ensure the absence of any mouse or human pathogens. Germ free mice were 
removed from sterile housing and immediately were administered a human fecal transplant. 
Fecal transplants were performed by thawing one aliquot and first gavaging the animals followed 
by topical application to all four paws and the urogenital region.  
 
Preparation of BLT and NSGhu mice and characterization of human reconstitution.  
 
BLT mice were prepared essentially as previously described [178-185, 187, 200]. Briefly, 
thy/liv implanted [250] and preconditioned NOD/SCID-gamma chain null (NSG) mice (Jackson 
Laboratories, Bar Harbor, ME) were transplanted with autologous human fetal liver CD34
+
 cells 
(Advanced Bioscience Resources, Alameda, CA) and monitored for human reconstitution in 
peripheral blood by flow cytometry [183, 185, 187]. Mice were maintained at the University of 
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North Carolina at Chapel Hill Division of Laboratory Animal Medicine in accordance with 
protocols approved by the Institutional Animal Care and Use Committee.  
 
Rectal exposure of HuMb BLT mice to HIV-1.  
 
A stock of HIV-1THRO [243] was prepared and titered as we have previously described 
[181, 252]. Mice were exposed rectally using 0.7 g p24 of HIV-1THRO (5x10
6
 TCIU). Rectal 
exposures with HIV-1THRO were performed essentially as previously described [184, 187] except 
that all the mucosal exposures were carried out atraumatically and without simulated rectal 
intercourse [253]. All rectal applications of vehicle or inhibitor as well as virus were performed 
while mice were anesthetized [184, 187]. After viral exposure, mice were returned to their 
housing to recover and were then monitored longitudinally for evidence of HIV-1 infection as 
indicated below (Figure 14). 
 
Vaginal or Oral exposure of HuMb BLT mice to HIV-1.  
 
A stock of HIV-1JR-CSF [243] was prepared and titered as we have previously described 
[181, 252]. Mice were exposed vaginally using 0.04 g p24 of HIV-1JR-CSF (3x10
5
 TCIU) 
atraumatically.Mice were exposed orally using 0.22 ug p24 HIV-11JR-CSF (1.6x10
6
 TCIU) . After 
viral exposure, mice were returned to their housing to recover and were then monitored 
longitudinally for evidence of HIV-1 infection as indicated below (Figure 15). 
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Analysis of HIV-1 infection of BLT mice.  
 
Infection of BLT mice with HIV-1 was monitored at the indicated time intervals in 
peripheral blood by determining plasma levels of viral RNA using real time PCR (limit of 
detection 750 copies/ml) [179, 180] and by monitoring CD4
+
 T cell percentages by flow 
cytometry [183, 184]. At necropsy, tissues were harvested and mononuclear cells isolated as 
previously described [178, 180, 183, 185, 187]. Mononuclear cells were washed, enumerated and 
tested using real time PCR for the presence of HIV-1 DNA (limit of detection 10 copies) [180, 
181, 183, 184]. 
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Figure 14 BLT mice with human microbiome have highest rectal HIV transmission 
efficiency 
 Mice were housed in four physically distinct animal rooms at the University of North 
Carolina, Genetic Medicine Building (GMB) animal facilities. GMB consists of two basement 
levels: the upper basement and the lower basement. Within these levels, the animal housing 
space is divided into a series of multi-room suites. Upper basement Room 40 (blue line, n=10) 
houses multiple strains of SPF mice from multiple laboratories and has communal air controlled 
hoods for animal housing. Upper basement Room 35 (red line, n =12) previously housed 
multiple strains of mice but was decontaminated and repourpased for our exclusive use. Lower 
basement Room 35C (black line, n=22) was a newly constructed space. Mice in the lower 
basement were received directly from Jackson Laboratories or bred in house in the lower 
basement. Lower basement Room 35D (green line, n=6) is a separate room used exclusively to 
house mice with a human microbiome.  
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Figure 15 BLT mice with human microbiome efficiently transmit HIV via vaginal or oral 
routes 
 Human microbiome BLT mice were exposed vaginally (black line) or orally (blue line) to 
3x10
5
 TCIU HIV-1JR-CSF. Human microbiome BLT mice were exposed orally (blue line) to 
1.4x10
6
 TCIU HIV-1JR-CSF  Peripheral blood was evaluated for detectable viral RNA each week 
post exposure. 
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CHAPTER VI. DISCUSSION AND FURTHER DIRECTIONS 
 
  
 In absence of a reliable cure or vaccine, transmission prevention is the only method 
available to contain the HIV/AIDS epidemic. Sexual transmission is the main contributor to HIV 
spread globally. Previous methods to prevent sexual transmission of HIV, such as male condoms, 
require consent and acceptance of the penetrive partner. Recently, Truvada was approved for use 
as oral PrEP but may not be an option for patients on other medications, who are unlikely to 
adhere to a daily regimen, or who simply do not prefer to take oral pills. Therefore, alternative 
methods such as topical microbicides may be an acceptable and effective addition to current HIV 
prevention options.  
 My work has focused on evaluating novel methods to prevent HIV transmission at 
mucosal sites. In vivo experiments utilizing humanized mice demonstrated that both vaginal and 
rectal HIV transmission can be prevented by utilizing topically applied antiretroviral drugs such 
as tenofovir or Maraviroc. Transmission of tenofovir resistant HIV was found to be greatly 
reduced when compared to wildtype virus. The transmitted founder virus HIVTHRO was found to 
transmit and replicate as well as the previously used viral strain common for laboratory research 
HIVJRCSF. Finally, a completely novel line of investigation was initiated by generating a 
humanized mouse model colonized with a human microbiome, HuMb BLT. This mouse model 
resulted in a higher rate of rectal transmission efficiency than any previous BLT model. Taken 
together, my work contributes to the immediate development of antiretroviral based PrEP 
strategies and can play a role in the novel investigations of microbial effect on HIV transmission 
and pathogenesis. 
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 Truvada for PrEP is the most recent development for HIV prevention and it will take 
years before its efficacy outside of clinical trials can be evaluated. Some of the questions to be 
answered include 1) What is the minimum adherence to Truvada needed to achieve significant 
protection? 2) Should there be a breakthrough infection, will the person taking Truvada as PrEP 
be at significant risk of developing antiretroviral resistance? 3) Most of all, will the people who 
are at greatest risk of HIV actually use Truvada as PrEP? Most of these questions will be 
answered in time. 
 There is strong support to develop more ART based PrEP strategies. As discussed in 
previous chapters, one direction of research is to develop a topical microbicide to deliver 
antiretroviral drugs to the vaginal or rectal mucosa prior to HIV exposure. A major benefit of this 
approach is that it parallels the already prevalent use of sexual lubricants [302, 303]. Therefore, 
acceptability could be very high [303, 304]. In addition, topical microbicides could be used peri-
coitally and may be effective immediately upon application as opposed to oral drugs which need 
time to reach the exposed tissues [31, 84, 274, 305, 306]. A drawback of topically administered 
PrEP is the greater potential for user error in dosing, proper application, etc. Therefore, it will be 
important to determine whether the efficacy of topical PrEP can overcome user error? Using a 
highly concentrated amount of drugs in topical formulations may ensure that even a partial dose 
will result in sufficient amount of drug presence to prevent HIV transmission. In fact, it has 
already been shown that topical administration of tenofovir results in far higher tissue 
concentrations than if the patient received tenofovir orally [84].  Topical administration of 
antiretroviral drugs may not result in the same side effects as orally administered drugs, such as 
bone mineral loss and interactions with other medications [307, 308]. Truvada for PrEP 
necessitates constant monitoring for breakthrough infection due to fear of breakthrough infection 
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followed by development of drug resistance. If a person has a breakthrough HIV infection while 
using topical PrEP, will they develop drug resistance? I believe this to be very unlikely due to the 
low to undetectable presence of ART drugs in the blood stream of patients using topical PrEP as 
well as the short duration of ART exposure compared to daily dosing of orally administered 
ART. This is a matter that can be addressed in animal models. If the concern for de novo drug 
resistance is eliminated, would it be possible for topical PrEP to be available over-the-counter? 
As mentioned before, acceptability is a large factor limiting current HIV prevention methods. 
Eliminating the need for doctor prescription would expand the availability of topical PrEP to at 
risk individuals who do not regularly see a doctor (i.e. healthy, young adults) and to individuals 
unlikely to ask a doctor for PrEP due to stigma. One could argue that over the counter 
dispensation removes a linkage to care. To which the counter argument is that these individuals 
had no linkage to care in the first place, nothing is being removed.  
 Long acting injectable drugs are under investigation for both HIV treatment and for 
protection [98]. Ideally, a patient receives an injection once a month and there is a continual, 
slow release of ART drugs over time sufficient to suppress ongoing infection or provide lasting 
protection against HIV acquisition. These could result in far better adherence than daily oral pills 
where accidently missing a dose is common. In terms of acceptability, industrialized nations tend 
to prefer pills to injections but this varies from individual to individual. In sub Saharan Africa, 
there is a strong precedent in place for long acting injectable birth control. Therefore, it may be a 
simple matter to pair the use of long acting injectable birth control with the use of long acting 
injectable HIV PrEP. This could be construed as a female-empowering form of HIV prevention 
given that the current most effective preventatives (condoms, male circumcision) require 
penetrive partner consent. A danger of long acting injectable ART is development of drug 
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resistance and side effects. Up to this point, any PrEP or ART can be effectively discontinued or 
altered upon the onset of drug resistance or side effects. Some long acting injectable drugs on the 
other hand may not be removed after injection. Should there be a breakthrough infection that is 
not fully suppressed by the injected ART, additional drugs will need to be added to prevent 
development of drug resistance. There is also the basic concern of adverse reactions to the drugs 
themselves. Ideally, a person could take an oral formulation of these drugs and monitor for 
adverse reactions prior to receiving the long acting inject able form.  
 The use of living microbes to prevent HIV transmission is the least developed of 
strategies due in part to its novelty and in part to the inherent difficulty of getting approvals to 
use self-replicating and/or genetically modified organisms in medicine. The idea of a living 
microbicide that can self replicate and potentially be spread to any sexual partner is both 
attractive and intimidating. The attraction of a living microbicide is that, in theory, 
administration to a single at risk individual will provide lasting protection to that individual and 
spread to all of their partners who will in turn transmit the organisms to their partners, much like 
an STD. Therefore, the living microbicide would reach the sexually active population most at 
risk of HIV infection without any need of administrators seeking them out. On the other hand, if 
an effective anti-HIV biological species is engineered to survive the intensely competitive 
vaginal and rectal compartments, is there a concern that this engineered species will then out 
grow and become invasive to the microbial community, resulting in a symptomatic dysbiosis. So 
far, this has not been the case in the studies evaluating these novel living microbicides. Actually, 
investigators have noticed that any administered biological organism is eventually out competed 
by indigenous species [309, 310]. While probiotics are a blossoming field with great potential, it 
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would take a great amount of time and data for a living HIV microbicide to take the place of 
current antiretroviral PrEPs under investigation. 
 In summary, the HIV epidemic is mainly perpetuated by sexual transmission despite 
currently available HIV prevention methods. Current popular HIV prevention methods require 
acceptance of the penetrating partner. While Truvada has been approved for PrEP, it is too early 
to determine if it will be effective outside of clinical settings. Treatment as PrEP is highly 
effective but requires a positive HIV status and a willingness to take ART early.  In short, new 
preventative methods are needed that can be used by the penetrated partner unbeknownst to the 
penetrating partner or that are more acceptable that condom use. Topical microbicides are under 
investigation as HIV PrEP and are gaining support for approval. Improvements in formulations 
and more clinical trials are necessary, but previous trials have found a high level of acceptability 
for microbicides [311]. Ultimately, HIV prevention strategies can only succeed if they are used. 
Therefore, acceptability is key to stemming the HIV epidemic. 
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